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The United States Pharmacopeia sets the standards for the manufacturing, storage, 
and analysis of medicinal formulations. One analysis, dissolution testing evaluates the 
rate at which the medicinal formulation forms a solution to predict in vivo drug release. 
Dissolution testing on ibuprofen tablets alone and in the presence of ascorbic acid or 
caffeine was performed to mimic the administration using orange juice or caffeinated soft 
drinks to assess their impact on the dissolution rate of ibuprofen. Results using the 
external calibration method produced a dissolution rate of ibuprofen that decreased 4% in 
the presence of ascorbic acid and increased 1% in the presence of caffeine. Figures of 
merit using current calibration methods such as external calibration method, standard 
addition method, and internal standard method via UV-Vis spectroscopy were performed 
via the same instrument producing errors from 0.18% to 1.3%. The figures of merit were 
then compared to a new method that combines the standard addition method and internal 
standard method first developed in 2015 for elements called standard dilution analysis. 
This high-risk, high reward attempt used the newly developed standard dilution analysis 
on complex molecules and Ultra-High-Performance Liquid Chromatography and 
produced errors from 11% to 15% that were attributed to pump pressure ripples. Biphenyl 
was then employed to verify the method first using current calibration methods producing 
errors from 3.4% to 14% and then compared to the standard dilution analysis that 
produced errors from 0.010% to 17%. The figures of merit were achieved via current 
calibration methods but due to variables involved with Ultra-High-Performance Liquid 
Chromatography analysis and the variability of the instrumentation, the standard dilution 
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CHAPTER 1 – INTRODUCTION 
1.10 History of Ibuprofen 
It is estimated that approximately 65% of human beings have turned to traditional 
medicines that incorporate plants into their modern medical care. After many decades of 
research on more than 150,000 plant species evidence has shown that plants display many 
diverse biological activities including secondary metabolites such as tannins, metabolized 
by the gut, that are used for the treatment of diarrhea, kidney and urinary issues, and 
display anti-inflammatory activity. In the development of new drugs, plants have been the 
primary source of substances that have provided novel compounds with pharmaceutical 
applications that treat various types of health conditions and are responsible for a 
considerable amount of the world’s prescription drugs.1 
The first documented use of plants being employed for medicinal purposes was 
etched onto stone tablets by the Assyrians in 4000B.C. in which they used willow leaves 
for the relief of joint pain in which the Sumerians of 3500B.C. then continued the use to 
reduce fevers, and then in 1300B.C. the Egyptians employed willow leaves in both the 
relief of joint pain and the reduction of fever. In 605B.C. the Babylonians continued the 
use of willow leaves but now employing them in the treatment of many different types of 
pain. Greeks like Hippocrates in 400B.C. and Dioscorides in 100A.D. employed willow 
leaves to reduce the pain of childbirth and reduce inflammation. The first clinical trial of 
willow bark and willow powder was performed by Edward Stone in 1763 publishing a 
letter on the benefits of the willow tree in the treatment of malaria, and in 1828 Johann 
Buchner successfully extracted and purified the active pharmaceutical ingredient of 




The structure of Salicin was finally resolved in 1838 by Raffaele Piria who then 
oxidized salicyl alcohol into salicylic acid with H. Gerland being the first to prepare 
salicylic acid in 1852. It was Charles von Gerhardt that first provided evidence of 
salicylic acids functional groups and then developed acetylsalicylic acid in 1853 after 
which Herman Kolbe and E. Lautemann developed an industrial scale production for 
salicylic acid that ended the use of willow powder. Felix Hoffman then synthesized 
acetylsalicylic acid in 1897 by acetylating the hydroxyl group of salicylic acid at the 
ortho position producing a more stable structure and on March 6th, 1899, acetylsalicylic 
acid was patented as Aspirin by the Bayer Company, and the first industrially produced 
nonsteroidal anti-inflammatory drug was born. However, none of these societies knew 
the mechanism of action until 1971 when John Vane blocked the biosynthesis of the pain 
messenger prostaglandin thus proving the analgesic properties of Aspirin.2,3 
When human beings are exposed to bacteria, microorganisms, irritants, toxins, 
burns, or other trauma that causes cell injury, an evolutionary survival mechanism and 
process of protection known as acute inflammation occurs that generates various local 
and systemic effects which may produce a hot and painful red swelling of the damaged 
area that may result in a loss of function in an attempt to restore homeostasis. If the acute 
inflammation is excessive, or lasts beyond 2 to 6 weeks, it may become chronic causing 
severe tissue damage, organ failure, and even death. Chronic inflammation can also be 
caused by diseases such as Alzheimer’s, diabetes, and cancer to name just a few. 
Inflammation is not a singular process, nor is it either on or off, but is modulated by 




deliver inflammatory cells to the damaged tissue diluting the inciting agent and isolating 
the damage from healthy tissue and blood so that healing may begin to occur.4,5 
When John Vane blocked the biosynthesis of the pain messenger prostaglandin in 
1971, he provided evidence that the mechanism of action of aspirin was the inhibition of 
cyclooxygenase which decreased prostaglandin production. In 1988 the structure of 
cyclooxygenase was clarified and the enzyme was cloned. However, aspirin caused many 
issues such as gastric ulcers, fever, and inhibited blood clotting. The causes of these 
issues were not identified until 1991 with the discovery of a second enzyme 
cyclooxygenase-2.6 
Arachidonic acid is a twenty-carbon omega-6 polyunsaturated fatty acid 
embedded as a phospholipid ester in cell membranes that contains four double bonds in 
cis position allowing for protein interaction due to its flexibility and may undergo non-
enzymatic reactions through autooxidation by reactive oxygen and nitrogen, or by way of 
enzymatic reactions. There are a family of enzymes referred to as phospholipases that 
assist in the release of arachidonic acid from membrane phospholipids referred to as 
phospholipase A2 which releases arachidonic acid in one step through hydrolysis of the 
phospholipid backbone and can travel through enzymatic pathways such as cytochrome 
P450, anandamide, lipoxygenase, and cyclooxygenase producing eicosanoids such as 
prostaglandins. When arachidonic acid is released from the phospholipid membrane 
cyclooxygenase-1 and cyclooxygenase-2 converts arachidonic acid in two sequential 
reactions. Arachidonic acid is oxidized to prostaglandin G2 (PGG2) followed by the 




synthases into five distinctly biologically active prostaglandins that act as secondary 
messengers.7,8 
Cyclooxygenase-1 is constitutively expressed in the cells and tissues, 
gastrointestinal tract, kidneys, and cardiovascular system indicating that it is 
developmentally regulated. Cyclooxygenase-1 stimulus regulates normal physiological 
processes essential for homeostasis providing protection of gastrointestinal mucosa, 
control of renal blood flow, autoimmune responses, pulmonary and central nervous 
system functions and cardiovascular and reproductive diseases. Cyclooxygenase-2 is 
located in the kidney and brain and is undetectable under normal physiological conditions 
but is upregulated and detectable after induction by inflammatory stimuli. 
Cyclooxygenase-1 in the gastrointestinal tract produce prostaglandins that exhibit 
cytoprotective effects on the gastrointestinal mucosa by reducing gastric acid secretion in 
the stomach increasing blood flow that stimulates the release of viscous mucus, and 
inhibition may cause gastrointestinal toxicities and ulcerations. Cyclooxygenase-1 in the 
vasculature produce prostaglandins that maintain the function of the kidneys by 
regulating normal blood flow and vascular tone, and inhibition leads to decreased 
glomerular filtration hindering the kidneys from filtering fluid and waste from the blood 
causing kidney damage. Cyclooxygenase-1 in the cardiovascular system produce 
prostaglandins that have pro-aggregatory effects that leads to platelet aggregation that 
causes coagulation of the blood assisting in the formation of blood clots at the sites of 
vascular injury, and inhibition decreases the regulation of vascular homeostasis 




Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are classified into four groups 
according to their inhibitory activities with traditional NSAIDs, like aspirin, in group 1 
having properties that inhibit both cyclooxygenase isoforms completely with little 
selectivity and is referred to as a nonselective inhibitor. Aspirin is also a noncompetitive 
and irreversible inhibitor binding to a separate location of cyclooxygenase thus changing 
its form and inactivating it through covalent bonding with its active site. A low dose of 
aspirin produces many desired effects with no systemic effects reducing platelet 
aggregation, sensation of pain, and fever, however, high doses of aspirin are required to 
induce anti-inflammatory activity which produces undesired effects that damage stomach 
mucosa leading to ulceration of the stomach and toxicity of the kidneys.6,8 
In the 1950’s aspirin was the most used over-the-counter drug in the treatment of 
pain and the administration of aspirin for diseases such as rheumatoid arthritis was the 
most popular, but only moderately effective compared to corticosteroids and opioids. 
However, the use of corticosteroids at the dosage required could become toxic, and the 
use of opioids came with a very high potential for addiction. Due to the adverse effects of 
aspirin, corticosteroids, and opioids in the treatment of rheumatoid arthritis, Dr. Stewart 
Adams began screening aspirin related salicylates and phthalates from 1952 to 1955 
using acute skin inflammation induced in guinea pigs which became the standard for 
testing the anti-inflammatory activity of compounds, but their activity was less than that 
of aspirin. In 1956 he presented his objective of developing a ‘safer aspirin’ that would be 
‘well tolerated by the gastrointestinal tract’ to the Boots Pure Drug Co. Ltd. by creating a 
chemical synthetic program with the help of chemist Dr. John Nicolson in which they 




assays. The compounds consisted of phenoxyphenyl and phenylalkanoic acids in which 
the phenoxyphenyl was unimpressive, however, the phenylalkanoic acids were further 
investigated leading to the decision to begin the screening of phenylacetic acids and 
phenylpropanoic acids.9 
Luckily, assays such as the Randall-Selitto Inflamed Paw-Pressure Test for 
analgesic activity and the Yeast-Fever Assay for antipyretic activity had been recently 
developed and made it possible to screen for the necessary therapeutic requirements for 
inflammation that controlled swelling, redness, heat and pain. This led to the selection of 
two clinically active phenylacetic acid candidates, however, both produced a skin rash in 
a significant number of patients and had to be dropped from consideration. Shortly after 
another phenylacetic acid candidate, ibufenac, was screened using the acute skin 
inflammation induced in guinea pigs and was found to be two to four times as potent as 
aspirin producing anti-inflammatory and analgesic activity at approximately half the 
dose. Ibufenac was eventually withdrawn from the market and further development due 
to hepatotoxicity.9 
Earlier studies of 4-propionic acids causing gastric ulcers in dogs were attributed 
to a very high plasma half-life and that the main ulcerogenic action in rats was systemic. 
Multiple studies were performed on the biodisposition of radiolabeled 4-substituted 
phenylacetic acids compared to 4-phenylpropionic acids providing evidence that the 
distribution of 4-phenylacetic acid in the body and accumulation in multiple organs were 
much more extensive than that of 4-phenylpropionic acids. These findings led Dr. Adams 
to the conclusion that phenylpropanoics with a long plasma half-life were higher in 




evidence led to the addition of a methyl group at the alpha carbon position of ibufenac 
modifying the acetic acid moiety to a propionic acid moiety producing ibuprofen in 1961, 
as seen below in Figure 1.9,10 
 
 
       Figure 1: The Structure of Ibuprofen10 
 
Initial screening of anti-inflammatory, analgesic, and antipyretic activities of 
ibuprofen were determined using the now standard screening methods showed that the 
activity of ibuprofen was sixteen to thirty-two times that of anti-inflammatory activity, 
thirty times that of analgesic activity, and twenty times that of antipyretic activity.9 
The Rheumatic Disease Unit in Edinburgh began clinical trials to determine the 
efficacy of a low daily dose of ibuprofen in rheumatoid arthritis patients shortly after it 
was patented in 1962. This study provided evidence that 300mg to 600mg of ibuprofen 
reduced the swelling and increased pressure tolerance in joints, and increased grip 
strength compared to high dose aspirin, which triggered the full-scale clinical 
development of ibuprofen in 1966. In 1967 a study on the metabolism of ibuprofen 
provided evidence of two main metabolites found in human urine that were isolated to 
reveal that ibuprofen was in fact a racemic mixture of (S) and (R) isomers. In 1969 
ibuprofen was approved in the United Kingdom for the treatment of rheumatoid arthritis 




that ibuprofen was more effective and relatively safe at higher doses the recommended 
daily dose was increased to 1200mg to 2400mg. Once it had been demonstrated that the 
therapeutic effects of ibuprofen were greater than that of aspirin the examination of 
ibuprofen’s effects on the gastrointestinal tract had to be evaluated. The most remarkable 
study was performed using patients with a history of peptic ulcers that were administered 
ibuprofen long-term in which approximately 10% displayed signs of gastric intolerance, 
and another notable study on gastrointestinal blood loss found in patients administered 
ibuprofen was noticeably less than that in patients administered aspirin. These studies 
confirmed that ibuprofen was a viable replacement for aspirin in the treatment of 
rheumatoid arthritis with greatly improved gastrointestinal tolerance.9 
In 1976 Dr. Adams investigated the pharmacological differences and 
contributions in the anti-inflammatory, analgesic, and anti-pyretic activities of 
ibuprofen’s (S) and (R) isomers. Earlier studies had shown that other phenylpropanoic 
acid compounds activity consisted essentially within the (S) configuration, and that the 
ability of nonsteroidal anti-inflammatory drugs to inhibit prostaglandin synthesis in vitro 
was quantitatively related to their activity in vivo.9 Dr. Adams found that in vitro the (S) 
isomer was highly active and the (R) isomer had very little activity, however, an 
inversion from the (R) to the (S) isomer occurred almost completely in vivo. The great 
successes in the study of ibuprofen’s safety record prompted the Boots Co. Ltd. to apply 
for non-prescription, over the counter, use in 1978 but was initially turned down in 1979 
claiming it was on the grounds of safety. An outside research group brought in by the 
Boots Co. Ltd. collected all the data from the 19,000 clinical trials and began new 




application, which was approved by the British government in 1983. Ibuprofen was 
approved for over-the-counter use in the United States soon after in 1984.9 
Since the discovery of cyclooxygenase-2 in 1991 there has been numerous 
advances in the field of pharmacology most importantly in pharmacokinetics and 
pharmacodynamics, which allowed for a closer look at the mechanism behind ibuprofen’s 
two isomers. Studies of the pharmacokinetics of ibuprofen determined that the oral 
administration of ibuprofen has a very short half-life (~3hrs.) and at therapeutic 
concentrations for anti-inflammatory, analgesic, and anti-pyretic effect (~10-50mg/L) it is 
almost completely bound to plasma proteins (>98%), which demonstrates ibuprofen’s 
quick absorption (~2hrs.) in the body. Ibuprofen’s low volume of distribution (~0.1-
0.2L/Kg) is consistent with the extent of plasma protein binding that occurs and with the 
ability to penetrate the central nervous system and accumulate at necessary peripheral 
sites for its anti-inflammatory and analgesic activity. Ibuprofen’s (R) isomer undergoes 
inversion (~65%) to the (S) isomer by way of an Acyl-CoA thioester that occurs 
predominantly in the liver, and to a lesser extent the gut. Ibuprofen is primarily 
metabolized in the liver by way of an oxidative metabolism via Cytochrome P450 
(CYP450) in which both isomers are metabolized by a CYP450 subset CYP2C9 and to a 
lesser extent the (R) isomer by the CYP450 subsets CYP2C8, CYP2C19, and CYP3A4. 
Elimination of ibuprofen occurs within 24 hours through urinary excretion (99%) and 
biliary excretion (1%) with a high rate of clearance (3-13L/hr.). Ibuprofen is classified as 
a non-selective inhibitor like aspirin, however, unlike aspirin it is a competitive and 
reversible inhibitor that binds to the active site of an enzyme preventing other substrates 




another substrate thus allowing the enzyme to bind with the competing substrate or allow 
the enzyme to resume its normal function. It was his early understanding into the 
necessity of a phenylpropanoic acid with a short half-life that provided Dr. Adams with 
the correct criteria for the selection of the proper drug candidate. He knew that the extent 
of gastrointestinal intolerance was directly related to the drugs half-life, and that the 
systemic accumulation of the drug was directly related to organ toxicity. It was these 
pharmacological properties that made ibuprofen the most commonly used and most 
frequently prescribed nonsteroidal anti-inflammatory drug on the market.9,11 
Drug interaction and synergy is the alteration in the pharmacological effect of one 
drug in the presence of another drug, food, drink, or environmental agent that occurs 
through pharmacokinetic interactions that affect absorption, distribution, metabolism, and 
excretion of the drug, or through pharmacodynamic interactions at the drugs site of 
action. The pharmacological effect of each drug may increase, decrease, or it can produce 
a completely new effect where these interactions may be beneficial or harmful. Many 
drug interactions occur through multiple mechanisms that act together and are frequently 
termed the “Mechanisms of Drug Interactions”.12 
Interactions that occur during absorption may decrease the amount of drug 
absorbed therefore decreasing the effectiveness of the drug or may increase the amount of 
drug absorbed thus increasing the probability of adverse effects or drug toxicity. 
Interactions that occur during distribution may affect the plasma protein binding of one 
drug by competition for the site of action by a second drug thus displacing the first drug 
activating it and increasing its concentration in plasma water that will not only affect the 




as well. The freed drug molecules are metabolized causing the bound drug molecules to 
become free allowing them to pass into solution to exert their pharmacological activity 
after which they are metabolized and excreted. The first drug has been metabolized and 
excreted prior to achieving stable blood plasma concentrations thus diminishing its 
therapeutic effect. Interactions that occur during metabolism may affect one drug when a 
second drug inhibits the metabolic enzymes used by the first drug and as the 
administration of the first drug continues its concentration increases until adverse effects 
or drug toxicity occurs, or the second drug may increase the formation of metabolic 
enzymes used by the first drug thus decreasing its concentration and the effectiveness of 
the first drug. Interactions that occur during excretion interferes with the liver’s biliary 
excretion and the kidneys urinary excretion of most drugs. Interference with the blood 
entering the renal arteries, renal tubules, or the disruption of the kidneys transport 
systems will increase or decrease urinary excretion or the reabsorption of drug molecules. 
Drug molecules are commonly conjugated making them water soluble allowing for 
biliary excretion and metabolism by gut flora for reabsorption, however, if a second drug 
has antibacterial activity the gut flora decreases thus reabsorption does not occur 
decreasing the concentration and the effectiveness of the first drug. Interference with 
transport proteins such as the bile salt export pump and solute carriers involved with the 
hepatic extraction and biliary excretion of drug molecules may decrease or even inhibit 
the flow of bile from the liver and affect renal extraction of drug molecules.12 
Alcohol is absorbed into the bloodstream from the gastro-intestinal tract, the 
target organ for most medication, and is referred to as ‘First-Pass’ metabolism in which 




form the toxic acetaldehyde, which is metabolized by aldehyde dehydrogenase to form 
acetate. However, CYP450 plays a crucial role in alcohol-medication interactions and in 
the presence of alcohol competition for the enzyme occurs and metabolism of the 
medication is hindered. When alcohol and ibuprofen are administered concurrently 
increasing concentrations of alcohol causes increasing dissolution of Ibuprofen, which 
when in the gastrointestinal tract leads to competition for CYP450 decreasing the 
metabolism and excretion of ibuprofen resulting in either overabsorption of ibuprofen 
causing an adverse reaction or undissolved ibuprofen resulting in organ damage. Food 
delays gastric emptying that frequently affects the rate of absorption of many drugs 
including nonsteroidal anti-inflammatory drugs. When Gingko Biloba and ibuprofen are 
administered concurrently the platelet-activating receptor antagonist, ginkgolide B, 
affects coagulation mechanisms resulting in reduced clotting, which is associated with 
prolonged bleeding times and subdural haematomas.11,12 
Aspirin is widely used for its anti-inflammatory, analgesic, anti-pyretic, and anti-
platelet activity. When aspirin and ibuprofen are administered concurrently ibuprofen 
competes for the binding site of COX-1 where aspirin may decrease ibuprofen’s serum 
levels without affecting the serum levels of salicylate, and ibuprofen antagonizes 
aspirin’s cardioprotective effect in platelets and increases gastrointestinal bleeding. 
Selective serotonin reuptake inhibitors are administered for the treatment of depression 
and increase the risk of gastrointestinal bleeding by 30%. When Selective Serotonin 
Reuptake Inhibitors (SSRIs) and ibuprofen are administered concurrently serotonin from 
the bloodstream is taken into platelets regulating the response to injury as it activates 




serotonin depletion and a 50-60% increase in gastrointestinal bleeding due to competition 
for the CYP450 subset CYP2C9. Anticoagulants like warfarin are administered for the 
treatment of blood clots in the legs and lungs. When warfarin and ibuprofen are 
administered concurrently the clotting tendency of blood decreases due to competition for 
the CYP450 subset CYP2C9 inhibiting the metabolism of warfarin and increasing its 
concentration until an over-anticoagulation effect or drug toxicity occurs. 
Antihypertensives like Angiotensin-Converting Enzyme (ACE) inhibitors are 
administered for the treatment of high blood pressure and heart problems. When ACE 
inhibitors and ibuprofen are administered concurrently an interference with the efficacy 
of the ACE inhibitor occurs in the kidney’s where vasoconstriction and fluid retention 
activate the renin-angiotensin system causing a significant increase in blood pressure due 
to the decrease in the hypotensive effect of the ACE inhibitor.11,12 
 
1.11 Dissolution Testing 
The United States Pharmacopeia (USP) is a non-profit organization founded in 
1820 with the goal of protecting and improving the health of all human beings by 
developing a set of regulatory standards for the quality control and quality assurance in 
the manufacturing and storage of human and animal drugs, over-the-counter medicines, 
and food ingredients ensuring that each individual item has the identical identity, 
strength, quality, purity, and consistency within a set tolerance. Each ingredient or 
preparation has a USP Monograph associated with it that includes the name, description, 
labelling requirements, packing and storage requirements, and specifications on testing 




also include the strength, quality, and purity required to meet USP standards. One such 
testing procedure is dissolution testing where the medicinal formulation is evaluated to 
determine the rate and extent in which it forms a solution under a controlled condition, 
which is then used to predict in vivo drug release profiles. The results of this testing 
ensure that the bioavailability of the medicinal formulation is not hindered by dissolution, 
but it does not definitively demonstrate sample bioavailability. However, failure in 
dissolution testing is an accepted sign of substandard performance and further evaluations 
must be performed.13,14,15,16 
Each Monograph provides the requirements for dissolution medium, apparatus, 
evaluation time, Certified Reference Material (CRM), sample solution, instrumental 
conditions, and evaluation tolerances. The media is placed into a vessel where a motor 
driven apparatus circulates it to simulate the environment of the gastro-intestinal tract. 
The medicinal formulation is then placed into the vessel and left to dissolve over a 
specific amount of time at body temperature. Samples of the solution are then drawn at 
different increments of time and analyzed under specific instrumental conditions. The 
quantitative data is then used to produce a Dissolution Profile and determine the 
percentage, or concentration, of Active Pharmaceutical Ingredient (API) dissolved and 
then compared to the evaluation tolerances provided in the Monograph.14 
The dissolution testing system employs six vessels, each a cylindrical container 
with a hemispherical bottom made from glass or other inert materials with volumes 
ranging from 100mL to 4000mL, however, 900mL vessels are most common. The shape, 
material, and manufacturing method play a crucial role in the precision of dissolution 




produce unreliable results, which can be resolved by employing injection molded glass 
vessels. Dosage forms evaluated in glass vessels may stick to the walls, which can be 
resolved by employing plastic vessels. There are many types of dissolution apparatus that 
are employed each designed for a specific dosage form and agitation method. When 
evaluating solid, beaded, or suspended dosage forms there are one of two apparatus that 
the monograph will require. The Basket, Apparatus 1, is connected to a steel shaft and is 
commonly designed as a cylinder consisting of a 40-mesh stainless steel screen 
containing the dosage form rotated at a rate of 100rpm inside of a 900mL vessel. 
Modifications to the basket such as 10-mesh to 100-mesh screens for use in 100mL to 
4000mL vessels, varying basket dimensions, and changing the rotation rate to 50rpm or 
75rpm are made depending on the dissolution performance desired for a specific dosage 
form. The Paddle, Apparatus 2, is connected to a steel shaft and is commonly designed as 
a hemispherical blade consisting of an inert material such as Teflon or stainless steel that 
is fixed above the dosage form rotating at a rate of 50rpm, 75rpm, or 100rpm. 
Modifications to the paddle such as reducing the dimensions producing a ‘mini-paddle’ 
for use in 200mL vessels are employed if very low concentration dosage forms are being 
evaluated.17,18 
The dissolution protocol checklist is performed beginning with referencing the 
monograph for the solid dosage forms to be examined to determine the testing parameters 
required. The apparatus is then selected, and any necessary modifications are performed. 
Parameters such as medium composition, quantity dissolved specifications, and rate of 
rotation are verified. The sampling method, sampling interval, and sampling analysis 




debris adhered to all surfaces assuring that they are transparent so that air bubbles in the 
medium can be detected, and more precise observations can be performed during the 
disintegration process. The bath temperature is then adjusted to 37oC. The vessels are 
installed, and the bath level is verified to be above the surface of the vessel medium. The 
medium is then prepared as per the individual monograph, degassed, and added to the 
vessels. The syringes, cannulas, filters, and the sampling access to the vessels are 
checked for any interferences that may hinder sampling or alter adsorption. Vessel 
sampling access is then configured so that the solid dosage forms can be inserted, and 
samples can be drawn efficiently.17 
The solid dosage forms are dropped as close to the center of the vessel, the clutch 
is engaged initiating paddle rotation, and the stopwatch started. Between each sampling 
interval detailed observations are recorded for each vessel. Each sample drawn is secured 
using airtight sample vials to assure no evaporation can occur. All samples are retained 
until the instrumental analysis has been completed and all calculations have been 
verified.17  
Once all dissolution samples have been secured a spectrophotometric absorption 
assay is performed as stated on the monograph for the API using a CRM standard, which 
is commonly performed via Ultraviolet and visible absorption spectroscopy (UV-Vis). 
Using Beer’s Law, the standard (s) of concentration (C) is analyzed within a cuvette of 
thickness (b) with the molar absorptivity of the API (a) to determine the absorbance of 
the standard (As), as seen below in Equation 1.
14 
 




The dissolution sample (u) of concentration (C) is then analyzed using a matching 
cuvette (b) with the same molar absorptivity (a) to determine the absorbance of the 
dissolution sample (Au), as seen below in Equation 2.
14 
 
𝐴𝑢 = 𝑎𝑏𝐶𝑢      (2) 
 
 The equations are then combined using the Beer’s Law relationship in which the 
molar absorptivity (a) and cuvette thickness (b) are removed, and the equation rearranged 
to produce Equation 3 below.14 
 
𝐶𝑢 = 𝐶𝑠 (
𝐴𝑢
𝐴𝑠
)      (3) 
 
The ratio method is an acceptable method, however, omitting a CRM in lieu of a 
calibration curve is permissible only if the API conforms to the Beer’s Law relationship. 
When implementing a calibration curve preparation of standards ranging between 75% to 
125% of the concentration required on the monograph for the assay of the API, after 
which the analysis is performed using the spectrophotometric absorption assay required 
in the monograph for the API.14 
 The tolerance, or the unit quantity (Q), of the labeled amount of API specified in 
the monograph is the amount dissolved in the specified amount of time, which is 
expressed as a percentage of the labeled content. The tolerance value is acceptable only if 
the dissolution test conforms to each Stage (Sn) of the acceptance table for the specific 




are evaluated are classified as Stage 1 (S1) in which each unit cannot be less than Q+5%. 
If the test satisfies S1 then it has met the required tolerance and no further evaluation is 
necessary, however, if the test does not meet S1 then the next stage of the evaluation must 
be performed. The next stage, Stage 2 (S2), requires that six more units be evaluated after 
which the average of the units from S1 and S2 is determined and must be equal to or 
greater than Q with no one unit less than Q-15%. If the test satisfies S2 then the test has 
met the required tolerance and no further evaluation is necessary, however, if the test 
does not meet S2 then the next stage of the evaluation must be performed. The next stage, 
Stage 3 (S3), requires that twelve more units be evaluated after which the average of the 
units from S1, S2, and S3 is determined and must be equal to or greater than Q with no 
two units less than Q-15%, and with no one unit less than Q-25%.14 
The difference factor (𝑓1) and similarity factor (𝑓2) test (𝑓-Test) is performed 
routinely to determine bioequivalence, or the expected biological equivalence, as to 
obtain biowaivers to allow pharmaceutical companies to be exempt from being required 
to perform timely and expensive bioequivalence studies. The 𝑓-Test is used to determine 
the bioequivalence of two different preparations of dosage units, different formulations, 
different strengths, different manufacturing methods, different compositions of 
components, or to compare a newly manufactured dosage unit to a dosage unit that has 
been stored for an extended period. The 𝑓-Test is also implemented to compare dosage 
forms from an identical batch. To perform a dissolution profile comparison the 
dissolution test is performed two separate times using twelve dosage units in each 
dissolution test performed under identical conditions, methods, and sampling times to 




one release value above 85%. The dissolution measurements should appropriately 
represent the dissolution profile with measurements being as spread out as possible. If 
mean data is to be used then the %CV must be no more than 20% for dissolution 
measurements at or below 15 minutes, and no more than 10% for all other measurements. 
The 𝑓1 test is the percent difference between the two dissolution profiles at individual 
measurement times, which represents the relative error between the two dissolution 
profiles. It is normalized and the acceptance value is based on a 10% average difference 
between the two dissolution profiles. The 𝑓1 test profile is identical if it has a value of 0 
and is considered not to be different if it has a value between 0 and 15. The 𝑓1 test is 
calculated using the sum of the number of measurement time points (n), the dissolution 
value of the reference batch at time t (Rt), and the dissolution value of the test batch at 










) ∙ 100    (4) 
 
The 𝑓2 test is the logarithmic reciprocal square root transformation of the sum or 
the error squared, which represents the measurement of similarity in the percent 
dissolution between the two dissolution profiles. The 𝑓2 test profile is identical if it has a 
value of 100 and is considered not to be different if it has a value between 50 and 100. 
The 𝑓2 test is calculated using the sum of the number of measurement time points (n), the 
dissolution value of the reference batch at time t (Rt), and the dissolution value of the test 
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The determination of the difference and similarity reflect the maximum and 
minimum change between two dissolution profiles and is an excellent tool which allows 
for the dissolution equivalence to be characterized in a simple approach.20 
 
1.12 Calibration Methods 
Quality assurance is responsible for the design of experimental procedures and the 
gathering and analysis of experimental data, which continually assists in the improvement 
of one another by determining and correcting systematic and random sources of error. 
The two components of a quality assurance program are quality control and quality 
assessment. The main purpose of quality control is to design specific protocols, methods, 
and techniques in the attempt to bring the analytical method under statistical control. This 
includes the collection, analysis, and identification of samples within a specific range of 
precision and accuracy. The main purpose of quality assessment is to confirm that the 
specific protocols, methods, and techniques developed by quality control have reached 
the state of statistical control required by state or federal regulations. In a laboratory 
setting it is the analytical chemist who performs the analysis and treats the raw data 
determining whether the specific protocol, method, or technique has reached that state of 
statistical control. The data the analytical chemist treats is commonly concentrations of 
known or unknown samples, or analytes, determined by applying a calibration method 
combined with a specific instrumental technique then reporting those quantities after 




confidence interval, and variance to name a few. Calibration is the process employed in 
which to assess and refine the accuracy and precision of analytical methods and 
instrumental techniques. Each calibration method employs reference samples known as 
standards that can range from two to as many as ten, which includes a ‘Blank’ that 
contains the medium and matrix involved in the analysis but does not contain any of the 
unknown analyte. There are two approaches each calibration method can utilize to 
determine the concentration of unknown analyte. The ratio approach and the graphical 
approach.21,22,23 
The ratio approach assumes that there is a linear relationship between the 
analytical signal produced by the instrumental technique and the concentration of known 
standards to determine the concentration of the unknown analyte, however, this 
assumption could be incorrect due to error in the preparation of the standard, noise from 
the instrument, or a matrix containing solvent or other substances surrounding the 
analyte. The graphical approach confirms this linear relationship by way of graphing the 
signal versus the concentration and then applies regression analysis. Regression analysis 
is a statistical tool that estimates the relationship between the signal (y) and the 
concentration (x) of the standard by minimizing the distance from a best-fit line, or 
trendline, to each datapoint on the graph in which the distance between them represents 
the error in the slope (m) and the intercept (b) of the trendline, as seen below in Equation 
6. 21,22,23 
 




The most common calibration method is the external calibration method (ECM) 
in which one or more external standards each containing known concentrations of analyte 
are prepared and analyzed separately from the unknown analyte. The ratio approach is 
employed as a single-point standardization where an external standard is analyzed and the 
signal measured (SS) for the known concentration (CS) and the sensitivity (kS) is then 
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The signal of the analyte is then measured (SA) and using the previously 
determined sensitivity of the external standard (kS) the concentration of the analyte (CA) 
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In the graphical approach, a blank and a minimum of three standards of increasing 
concentrations are analyzed after which the signal of each standard (Ss) is plotted on the 
y-axis and their concentrations (Cs) are plotted on the x-axis where the trendline will 
intercept (b) at zero, and where the slope (m) of the line represents the sensitivity (kA). 
The calibration curve equation is then rearranged to use the analytes signal (SA) on the y-










However, if the matrix of the analyte is unknown than the ECM is not 
implemented due to the matrix of the calibration method being much less complicated 
than that of the analyte, which will then alter the signals sensitivity (kS). If there is error 
in the preparation of one of the external standards the total error remains very small due 
to the other external standards maintaining a linear relationship with the sensitivity (kA). 
When the ECM cannot be implemented due to mismatched matrices between the standard 
and the analyte it is commonplace to implement the standard addition method (SAM). 
21,22,23 
In the ratio approach, there are several ways to approach the SAM method. For 
example, a constant volume of analyte (VA) is added to two volumetric flasks after which 
a volume of external standard (VS) at a known concentration (CS) is added to one of the 
volumetric flasks, referred to as a spike. Each are then topped with solvent to produce a 
final volume (VF). The solutions are then analyzed producing one signal for the pure 
analyte (SA) and one signal for the spiked analyte (SA+S), after which the concentration of 
the unknown analyte (CA) can be determined, as seen below in Equations 10 and 11 


















In the graphical approach, the signal for the spiked analyte (SA+S) is plotted on the 
y-axis and the concentration of spiked standard (CS) is plotted on the x-axis where the 
trendline intercepts (b) on the y-axis, and the slope (m) of the line represents the 
sensitivity. The calibration curve equation is then rearranged to solve for the x-intercept 
by setting the y-axis to zero. Again, beginning with Equation 6, the concentration of 
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When there is a possibility of analyte loss during sample preparation such as 
spillage or evaporation, instrumental drift due to variation in the radiation sources energy 
or intensity, variation in sample injection volumes, or the necessity for improved 
accuracy and precision, the internal standard method (ISM) is implemented. The ISM is 
generally implemented using a single standard that employs a known concentration of a 
compound that is similar in concentration, chemical properties, and within the same 
wavelength excitation range as the analyte, referred to as the internal standard (IS), which 
is added to the blank, standard, and analytes to be used in the instrumental analysis. Due 
to the IS being added to the analyte during sample preparation the ratio of IS to the 
analyte is constant. If there is any loss of analyte due to spillage or evaporation, then the 
loss of IS will be proportional. This proportionality is also observed during the 
instrumental analysis. If there is a variation in the radiation sources energy or intensity, or 




In the ratio approach the signal of analyte measured (SA) is directly proportional 




𝑆𝐴 = 𝑘𝐴𝐶𝐴      (13) 
 
 Similarly, the signal of IS measured (SI) is directly proportional to the IS 
concentration (CI) and sensitivity (kI), as seen below in Equation 14.
 21,22,23 
 
𝑆𝐼 = 𝑘𝐼𝐶𝐼      (14) 
 
 Since the two signals are directly proportional Equation 8 and Equation 9 can then 
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 The sensitivity of the two signals will then be constant over a wide range of 
conditions. If the signal of analyte increases due to change in temperature or flow rate, 
then the signal of the IS increases proportionally, referred to as the relative response 
factor (K), and the sensitivities can be combined and rearranged to produce the ISM 











 The relative response factor (K) must be determined prior to analysis and is 
determined by rearranging Equation 11. This is performed by analyzing a standard of 
known concentration (CS) consisting of the same chemical species as the analyte to 
determine its response (SS) in relation to the response of the IS (SI) at known 
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 The relative response factor (K) determined in Equation 17 is then used in the 
analysis of the unknown concentration of analyte (CA) producing the measured signal 
(SA) in relation to the measured signal of IS (SI) of known concentration (CI) using the 
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 Lastly, the unknown concentration of analyte (CA) can be determined by 
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 In the graphical approach, the IS concentration is held constant for all standards 




on the y-axis (
𝑆𝑆
𝑆𝐼
) and the standard concentration (CS) is plotted on the x-axis where the 
trendline intercepts (b) on the y-axis and the slope (m) of the line represents the 
sensitivity. The samples are analyzed subsequently and ratio of the analyte signal (SA) to 
IS signal (SI) is calculated. Referring to Equation 6, the calibration curve equation is then 
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1.13 Standard Dilution Analysis 
A new calibration method that combines both the SAM and ISM has been 
evolving since 2015 called Standard Dilution Analysis (SDA), which corrects for matrix 
effects and interferences caused by instrumental variations and non-spectral signal 
fluctuations in analyte properties and positioning. Empirical evidence gathered from 
current research shows that SDA produces more precise Figures of Merit than that of 
ECM, SAM, and ISM when implemented individually. There are two requirements an 
instrumental technique must meet prior to implementation of SDA. The Instrument must 
have the ability to accept liquid samples and monitor a minimum of two wavelengths 
simultaneously. As of today, SDA has only been performed in the analysis of elements 
and small molecules such as hydrogen chloride, nitric acid, and ethanol. However, it has 
not yet been attempted in both the analysis of larger molecules and employing Ultra 




SDA Calibration method is carried out by preparing a standard solution consisting of the 
analyte (A) with an internal standard (I) that when analyzed produces a signal for the 
analyte (SA) that originates from the sample (sam) and the standard (std), which is 
monitored at one wavelength (λ1) while simultaneously monitoring the signal from the 
internal standard (SI) at a second wavelength (λ2). Each signal is equal to the calibration 
sensitivity (m) which is multiplied by the individual species concentrations (mACA) and 























When the data is used to produce a calibration curve the ratio of analyte signal to 
internal standard signal is plotted on the y-axis (
𝑆𝐴
𝑆𝐼




) on the x-axis, which produces the slope and intercept, as seen 












     (23) 
 
To prepare the solutions for SDA analysis the sample containing the unknown 
analyte (A) is combined with the standard and the internal standard at a fixed ratio, as 







= 𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡     (24) 
 
If the amount of the sample continues to be constant during solution preparation, 




) remains constant along with the intercept, and the concentration of the unknown 










    (25) 
 
Since the standard solution contains a fixed ratio of analyte (A) to internal 
standard (I) the concentration can be determined by the calibration plot. However, there 
are three contributing factors that must be addressed prior to analysis: (1) Assuring that 
the analyte (A) and internal standard (I) contain concentrations in the calibration curves 
dynamic range, (2) The mixture contains no other contributing species, and (3) Spectral 
interferences are measured beforehand, and the signals normalized. If these caveats 
cannot be addressed, then SDA will fail.24 
 
1.14 Figures of Merit 
Upon completion of the instrumental analysis, method validation is performed to 
determine the Figures of Merit (FOM). The analytical data is then used to calculate the 
sample mean (?̅?) by summing all the samples (xn) then dividing the sample sum by the 












    (26) 
 
 The sample standard deviation (s) is then calculated by taking the square root of 
the square of the sample mean (?̅?) subtracted from each of the samples (xn) divided by the 





      (27) 
 
 The percent error is then calculated by taking the absolute value of the 
experimental value subtracted from the theoretical value that is then divided by the 






∙ 100  (28) 
 
The percent relative standard deviation (%RSD) is then calculated by dividing the 
sample standard deviation (s) by the sample mean (?̅?) then multiply by one hundred, as 










The lowest concentration of analyte the instrumental technique can detect, or limit 
of detection (LOD), is then determined by multiplying the sample standard deviation (s) 





      (30) 
 
The lowest concentration of analyte the instrumental technique can quantify, or 
limit of quantitation (LOQ), is then determined by multiplying the sample standard 






      (31) 
 
 Lastly, from LOQ to the Limit of Linearity (LOL), the point at which the signal 
ceases to maintain a linear relationship with the analyte concentration, is the Linear 
Dynamic Range (LDR), or the range in which the signal maintains a linear relationship 
with the concentration of analyte, as seen below in Equation 32.28 
 
𝐿𝐷𝑅 = 𝑓𝑟𝑜𝑚 𝐿𝑂𝑄 𝑡𝑜 𝐿𝑂𝐿    (32) 
 
1.15 Ultra-High-Performance Liquid Chromatography 
 Chromatography is the analytical technique that separates the complex 




liquid that is fixed inside of a cylinder where the gas or liquid mobile phase moves the 
chemical mixture across the stationary phase where analytes of the chemical mixture 
having different strength affinities for the components in the stationary phase are retained 
through a variety of mechanisms. The analytes return to the mobile phase at different 
times thus separating each component in the chemical mixture.22 
 High-Performance Liquid Chromatography (HPLC) employs high pressure 
pumps that push the liquid mobile phase at a set rate through a system of plumbing at a 
maximum pressure of approximately 5,800psi and temperatures up to 40oC. The chemical 
mixture is injected in volumes between 5-50µL into the flowing mobile phase by a 
syringe or a prefilled ‘sample loop’. The stationary phase consists of many fine spherical 
microporous silica particles between 3-5.0µm diameter containing large surface areas 
with stationary phase coatings.22 
 There are two types of phases employed in liquid chromatography. The normal-
phase liquid chromatography is where the stationary phase is composed of a polar 
packing material such as silica with hydroxyl groups and employs a less polar liquid 
mobile phase where the more nonpolar components of the chemical mixture leave from 
the column first. The reverse-phase liquid chromatography is where the stationary phase 
is composed of a nonpolar entity such as octadecylsilane (C18) and employs a more polar 
liquid mobile phase where the more polar components of the chemical mixture leave 
from the column first.22  
 The analyte, in the process of partition chromatography, partitions between being 
dissolved in the liquid mobile phase or the bonded stationary phase. The time the analyte 




analytes leave the column, they cross a detector which is most often a UV-Vis detector. 
The results are sent to the instrument’s computer data station where the signal is 
converted and displayed graphically as a chromatogram. A chromatogram is a graph that 
displays the detector response as a function of the displacement of the molecules in the 
chemical mixture over time. The display is a series of colored peaks representing the 
signal response of the analytes in the chemical mixture. Finally, the mobile phase and 




          Figure 2: A High-Performance Liquid Chromatography System30 
 
  Ultra-High-Performance Liquid Chromatography (UHPLC) functions under the 
same principles as HPLC, however, it employs smaller inner diameter tubing, a 
maximum pressure of approximately 19,000psi, temperatures as high as 65oC, injection 





There are many chromatography parameters that make up the chromatogram. The 
retention time (tr) is the time it takes for the molecules in the chemical mixture to be 
injected into the column and the time the molecules take to reach the detector. The 
resolution (Rs) is the measure of the separation between two adjacent chromatographic 
peaks where a higher value denotes a better separation, with 1.5 being required for 
baseline separation. The capacity factor (k’) is the measure of the interaction, or 
retention, of the molecules in a chemical mixture and the chromatographic column where 
a value between 1 and 5 is optimal. The efficiency of a chromatographic peak measures 
the dispersion of the molecules in the chemical mixture as it flows through the column. 
The two parameters that make up column efficiency are theoretical plate number and 
plate height. Theoretical plates are the division of equilibrations of the molecules in the 
chemical mixture that are partitioned between the mobile phase and stationary phase. The 
plate number (N) is the measure of the dispersion of the molecules in the chemical 
mixture as it flows through the column, and the plate height (HETP) is the column length 
required for one equilibration of the molecules in the chemical mixture. The tailing factor 
(Tf) is a representation of the asymmetry in the chromatographic peak band shape. The 
selectivity factor (α), or sensitivity, is the measure of a chromatographic systems ability 
to differentiate between different molecules in the chemical mixture where the greater the 






1.16 Research Goals 
 This research will evaluate the dissolution rate of 200mg ibuprofen tablets as per 
the USP monograph in the presence of ascorbic acid or caffeine to mimic the 
administration of the active pharmaceutical ingredient using orange juice and caffeinated 
soft drinks, respectively. A comparative analysis of the figures of merit will be performed 
for the external calibration method (ECM), the standard addition method (SAM), the 
internal standard method (ISM), and the standard dilution analysis (SDA) method. The 
empirical evidence gathered by the research will increase current knowledge of 1) the 
effect of added beverage constituents on dissolution rates and 2) the utilization of SDA 
by HPLC. 
The standard dilution analysis (SDA) method has only been employed in the 
analysis of colored dyes (Visible Spectroscopy)24, elements (ICP-OES)25,27, and ethanol 
(Raman Spectroscopy)26. Superior figures of merit have been reported. Only UV-Vis 
Spectroscopy, Raman Spectroscopy, and ICP-OES have been employed in the analyses to 
date. SDA has not been employed in the analysis of other molecules nor has it been 
employed via UHPLC as the analytical technique. This research is a high risk, high 
reward first attempt employing SDA on UHPLC. Since SDA is the combination of SAM 
and ISM, a large time commitment to one unknown sample occurs and this time 
commitment increases due to the nature of chromatography. By utilizing an automated 





CHAPTER 2 – MATERIALS AND METHODS 
2.10 Materials, Equipment, and Instrumentation Employed 
 The list of chemicals, disposable products, equipment, and instrumentation 
employed in the research were tabulated for quick reference, as seen below in Table 1 to 
Table 4, respectively. 
 
Table 1: List of Chemicals 
 
 
Table 2: List of Disposable Products 
 
  
Chemical CAS Purity/Grade Physical State Mfg. Name Mfg. Location
Monobasic Potassium Phosphate 7778-77-0 Ultrapure Bioreagent Crystal, Solid J.T. Baker Phillipsburg, NJ
Sodium Hydroxide 1310-73-2 40% (w/w) Aqueous, Liquid VWR Chemicals Radnor, PA
L-Ascorbic Acid, ACS 50-81-7 ≥99% Powder, Solid Fisher Chemical Pittsburg, PA
Caffeine, USP/FCC 58-08-2 ≥98.5% Anhydrous, Solid Fisher Chemical Pittsburg, PA
Formic Acid 64-18-6 90% Aqueous, Liquid Fisher Chemical Pittsburg, PA
Methanol 67-56-1 LC/MS Grade Liquid Fisher Chemical Pittsburg, PA
Ammonium Hydroxide 1336-21-6 28-30% Aqueous, Liquid VWR Chemicals Radnor, PA
Acetonitrile 75-05-8 LC/MS Grade Liquid Fisher Chemical Pittsburg, PA
Water 7732-18-5 LC/MS Grade Liquid Fisher Chemical Pittsburg, PA
Ibuprofen, USP 15687-27-1 ≥97% Powder, Solid Spectrum Chemical New Brunswick, NJ
Benzoic Acid 65-85-0 99% Crystal, Solid Alfa Aesar Ward Hill, MA
Biphenyl 92-52-4 99.5% Crystal, Solid Eastman Kodak Rochester, NY
Naphthalene 91-20-3 99% Crystal, Solid Acros Organics Geel, Belgium
Item Model Volume/Size/Pore Material/Description Catalog Mfg. Name Mfg. Location
Membrane Filter Durapore 47mm x 0.45um Hydrophilic Polyvinylidene Fluoride HVLP04700 Merck Millipore Burlington, MA
Storage Bottle Nalgene 1L Narrow-Mouth High-Density Polyethylene Resin 2002-0032 Thermo Fisher Scientific Waltham, MA
Sample Test Tube Culture Tubes 16mm x 150mm Borosilicate Glass 14-961-31 Thermo Fisher Scientific Waltham, MA
Micropipette Tip Yellow Redi-Tip 1-200uL Polypropylene Resin 02-681-2 Thermo Fisher Scientific Waltham, MA
Micropipette Tip Blue Redi-Tip 100-1000uL Polypropylene Resin 02-681-4 Thermo Fisher Scientific Waltham, MA
LC Sample Vial Convienience Kit 2mL 12mm x 32mm Clear Glass 13-622-188 Thermo Fisher Scientific Waltham, MA
Syringe Luer-Lok 10mL Polypropylene Resin 309604 Becton, Dickinson & Co. Franklin Lakes, NJ
Filter Luer-Lok 25mm x 0.45um Nylon CH4525-NN Thermo Fisher Scientific Waltham, MA




Table 3: List of Equipment 
 
 
Table 4: List of Instrumentation 
 
 
2.11 Dissolution Testing Medium 
Unmodified Dissolution Medium 
The parameters and medium used in the dissolution testing of ibuprofen tablets, 
followed the USP35-NF30, and employed a pH 7.2 phosphate buffer. A 0.2M monobasic 
potassium phosphate solution was prepared by adding 27.22g of monobasic potassium 
phosphate to a 1L volumetric flask topped to the volumetric line with DI water. A 0.2M 
sodium hydroxide stock was then prepared by adding 18.0mL of 40% (w/w) sodium 
hydroxide to a 1L volumetric flask topped to the volumetric line with DI water. The 
solutions were stirred by magnetic stir bars until homogeneous. This procedure was 
performed two times for each dissolution test performed. The solids were measured using 
Item Model/Series Description Model Number Mfg. Name Mfg. Location
Deionized Water System Picosystem 18MΩ cm
-1
 ASTM/CAP Type 1 Reagent Grade ET-11218 Hydro Atlanta, GA
Volumetric Pipettes Fisherbrand To Deliver ±0.003mL @ 20oC 13-650 Thermo Fisher Scientific Waltham, MA
Micropipettes Reference 10-100uL Single-Channel Variable-Volume 4910000042 Eppendorf Enfield, CT
Micropipettes Reference 100-1000uL Single-Channel Variable-Volume 22470302 Eppendorf Enfield, CT
Vision Classic 6 Dissolution Tester DS-00-0145
Easi-Lock USP Precision 1L Glass Vessels (Serialized) 74-104-101
USP PDVF 1L Spin-Paddles (Serialized) 74-105-201
Easi-Lock Vessel Covers 74-104-151
Easi-Lock Vessel Cover Plugs 74-107-006
Vision 1/8" Peek Manual Sampling Cannula Luer-Lok Adapter 74-104-201





Instrument Model Description Model Number Mfg. Name Mfg. Location
Analytical Balance New Classic MF 0.0001g Readability AL204 Mettler-Toledo Greifensee, Switzerland
Analytical Balance Fisher Science Education 0.01g Readability ALF2002 Thermo Fisher Scientific Waltham, MA
Dual-Beam Monochromator
Full Spectrum Xenon Pulse Lamp
Dual Silicon Diode Detectors
Quartz Covered Optics
Communications Bus Unit CBM-20A
Solvent Delivery Unit LC-30AD
Solvent Degassing Unit DGU-20A5R
Automatic Sampling Unit SIL-30AC
Column Oven Unit CTO-20A
Multi-Wavelength Detector Unit SPD-30AM
Ultra-High-Performance 
Liquid Chromatography
Nexera X2 Shimadzu Columbia, MD
UV-Vis 
Spectrophotometer




an analytical balance with a 0.0001g readability and the volumes were measured using 
volumetric pipettes. 
To prepare the pH 7.2 phosphate buffer 750.0mL of 0.2M potassium phosphate 
monobasic solution, 520.5mL of 0.2M sodium hydroxide solution, and 1729.5mL of DI 
water was measured using a 1L graduated cylinder and then added to a 3L Erlenmeyer 
flask and stirred for 15 minutes. Depending on the acidity or basicity of the phosphate 
buffer the pH was measured and adjusted to 7.2 either using a 1.0M monobasic potassium 
phosphate solution (prepared by adding 68.0430g of potassium phosphate monobasic to a 
500mL volumetric flask topped to the volumetric line with DI water), or a 2.0M sodium 
hydroxide solution (prepared by adding 90.1mL 40% w/w sodium hydroxide to a 500mL 
volumetric flask topped to the volumetric line with DI water). 
The phosphate buffer was then deaerated by heating above 41oC while stirring. 
The deaerated phosphate buffer was then filtered through a 0.45µm PDVF 47mm 
membrane filters using a 300mL Millipore 47mm glass vacuum filtration systems and 
then stirred under vacuum for five minutes. Immediately after five minutes the medium 
was placed into a 1L graduated cylinder and its mass was adjusted to 900g using a top-
loading balance with a readability of 0.01g. Each volume placed into the six dissolution 
vessels was within ±1% of the required 900g. This procedure was performed twice 
producing 6L of deaerated pH 7.2 phosphate buffer for the dissolution testing of 
ibuprofen. Each dissolution test employed approximately 5400mL with approximately 






L-Ascorbic Acid Modified Dissolution Medium 
To mimic the administration of ibuprofen tablets using 8 fl. oz. of orange juice 
containing 82.0mg of L-ascorbic acid a modification to the pH 7.2 phosphate buffer was 
performed prior to the deaeration procedure by adding 0.2460g of L-ascorbic acid to each 
of the 3L Erlenmeyer flasks containing the pH 7.2 phosphate buffer and then stirred for 
15 minutes. The pH was measured and adjusted to pH 7.2 then deaerated as previously 
described. 
 
Caffeine Modified Dissolution Medium 
To mimic the administration of ibuprofen tablets using 12 fl. oz. of caffeinated 
soda containing 34.0mg of caffeine a modification to the pH 7.2 phosphate buffer was 
performed prior to the deaeration procedure by adding 0.1020g of caffeine to each of the 
3L Erlenmeyer flasks containing the pH 7.2 phosphate buffer then stirred for 15 minutes. 
The pH was measured and adjusted to pH 7.2 then deaerated as previously described. 
 
2.12 Mobile Phases 
Ibuprofen and Benzoic Acid (Mobile Phase A) 
A (40:60) 1% formic acid (v/v) in water at pH 2.5 and acetonitrile mobile phase 
was prepared by transferring 11.1mL of formic acid to a 1L volumetric flask diluted with 
LC/MS grade water. The pH was adjusted to pH 2.5 by transferring 0.5mL of ammonium 
hydroxide to the 1L of 1% formic acid solution after which 400mL was transferred to a 
1L graduated cylinder and 600mL of LC/MS grade acetonitrile was then transferred to 
the 1L graduated cylinder. The (40:60) mixture of 1% formic acid in water at pH 2.5 and 




Biphenyl and Naphthalene (Mobile Phase B) 
A (30:70) water and acetonitrile mobile phase was prepared by transferring 
300mL of LC/MS grade water and 700mL of LC/MS grade acetonitrile to a 1L graduated 
cylinder. The (30:70) mixture of water and acetonitrile was then transferred to a 1L 
Nalgene bottle. 
 
2.13 Determination of the Lambda Max 
Ibuprofen and L-Ascorbic Acid 
Samples for the determination of the lambda max for ibuprofen and L-ascorbic 
acid individually, and in a mixture were prepared by adding 0.1000g of ibuprofen to a 
100mL volumetric flask topped to the volumetric line with unmodified dissolution 
medium to produce a 1,000mg/L ibuprofen stock solution. All subsequent solutions from 
this stock were topped to the volumetric line with unmodified dissolution medium. A 
50mg/L ibuprofen sample was prepared by transferring 5.0mL of the 1,000mg/L 
ibuprofen stock solution to a 100mL volumetric flask. A 1,000mg/L L-ascorbic acid 
stock solution was prepared by adding 0.1000g of L-ascorbic acid to a 100mL volumetric 
flask. A 50mg/L L-ascorbic acid sample was prepared by transferring 5.0mL of the 
1,000mg/L L-ascorbic acid stock solution to a 100mL volumetric flask. A 50mg/L 
ibuprofen and 50mg/L L-ascorbic acid sample mixture was prepared by adding 5.0mL of 
the 1,000mg/L ibuprofen stock solution and 5.0mL of the 1,000mg/L L-ascorbic acid 






Ibuprofen and Caffeine 
Samples for the determination of the lambda max for ibuprofen and caffeine 
individually, and in a mixture were prepared by adding 0.0200g of ibuprofen to a 50mL 
volumetric flask topped to the volumetric line with unmodified dissolution medium to 
produce a 0.40mg/L ibuprofen stock solution, and all subsequent solutions prepared from 
this solution were topped to the volumetric line with unmodified dissolution medium. A 
0.025mg/L ibuprofen sample was prepared by transferring 1.56mL of the 0.40mg/L 
ibuprofen stock solution to a 25mL volumetric flask. A 0.40mg/L caffeine stock solution 
was prepared by adding 0.0200g of caffeine to a 50mL volumetric flask. A 0.025mg/L 
caffeine sample was prepared by transferring 1.56mL of the 0.40mg/L caffeine stock 
solution to a 25mL volumetric flask. A 0.40mg/L ibuprofen and caffeine stock solution 
was prepared by adding 0.2000g of ibuprofen and 0.2000g of caffeine to a 50mL 
volumetric flask. A 0.025mg/L ibuprofen and caffeine sample mixture was prepared by 
transferring 1.56mL of the 0.40mg/L ibuprofen and caffeine stock solution to a 25mL 
volumetric flask. 
 
Ibuprofen and Benzoic Acid 
Samples for the determination of the lambda max for ibuprofen and benzoic acid 
individually, and in a mixture were prepared by adding 0.1000g of ibuprofen to a 5mL 
volumetric flask topped to the volumetric line with LC/MS grade methanol to produce a 
20,000mg/L ibuprofen stock solution. A 1,000mg/L ibuprofen stock dilution was 
prepared by transferring 0.50mL of the 20,000mg/L ibuprofen stock solution to a 10mL 
volumetric flask topped to the volumetric line with the (40:60) 1% formic acid in water at 




transferring 0.25mL of the 20,000mg/L ibuprofen stock solution to a 10mL volumetric 
flask topped to the volumetric line with the (40:60) 1% formic acid in water at pH 2.5 and 
acetonitrile mobile phase. A 20,000mg/L benzoic acid stock solution was prepared by 
adding 0.1000g of benzoic acid to a 5mL volumetric flask topped to the volumetric line 
with LC/MS grade methanol. A 150mg/L benzoic acid stock dilution was prepared by 
transferring 0.075mL of the 20,000mg/L benzoic acid stock solution to a 10mL 
volumetric flask topped to the volumetric line with the (40:60) 1% formic acid in water at 
pH 2.5 and acetonitrile mobile phase. A 75mg/L benzoic acid sample was prepared by 
transferring 0.038mL of the 20,000mg/L benzoic acid stock solution to a 10mL 
volumetric flask topped to the volumetric line with the (40:60) 1% formic acid in water at 
pH 2.5 and acetonitrile mobile phase. A 500mg/L ibuprofen and 75mg/L benzoic acid 
sample mixture was prepared by mixing 5mL of the 1,000mg/L ibuprofen stock dilution 
with 5mL of the benzoic acid stock dilution together in a test tube. 
 
Biphenyl and Naphthalene 
Samples for the determination of the lambda max for biphenyl and naphthalene 
individually, and in a mixture were prepared by adding 0.0100g of biphenyl to a 100mL 
volumetric flask topped to the volumetric line with the (30:70) water and acetonitrile 
mobile phase to produce a 100mg/L biphenyl stock solution. All subsequent solutions 
were diluted to the volumetric line with the (30:70) water and acetonitrile mobile phase. 
A 10mg/L biphenyl sample was prepared by transferring 1.0mL of the 100mg/L biphenyl 
stock solution to a 10mL volumetric flask. A 100mg/L naphthalene stock solution was 




naphthalene sample was prepared by transferring 1.0mL of the 100mg/L naphthalene 
stock solution to a 10mL volumetric flask. A 10mg/L biphenyl and naphthalene sample 
mixture was prepared by transferring 1.0mL of the 100mg/L biphenyl stock solution and 
1.0mL of the naphthalene stock solution to a 10mL flask. 
 
2.14 Determination of the Limit of Detection and Limit of Quantitation 
Ibuprofen 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with unmodified 
dissolution medium. Ibuprofen samples from 2.0mg/L to 20mg/L in 2.0mg/L increments 
along with a 1.0mg/L sample were prepared from the 1,000mg/L ibuprofen stock solution 
using 100µL and 1000µL micropipettes to transfer to eleven 10mL volumetric flasks 
topped to the volumetric line with unmodified dissolution medium. 
 
Ibuprofen and L-Ascorbic Acid 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with L-ascorbic acid 
modified dissolution medium. Ibuprofen samples from 2.0mg/L to 20mg/L in 2.0mg/L 
increments along with a 1.0mg/L sample were prepared from the 1,000mg/L ibuprofen 
stock solution using 100µL and 1000µL micropipettes to transfer to eleven 10mL 






Ibuprofen and Caffeine 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with caffeine 
modified dissolution medium. Ibuprofen samples from 2.0mg/L to 20mg/L in 2.0mg/L 
increments along with a 1.0mg/L sample were prepared from the 1,000mg/L ibuprofen 
stock solution using 100µL and 1000µL micropipettes to transfer to eleven 10mL 
volumetric flasks topped to the volumetric line with caffeine modified dissolution 
medium. 
 
Biphenyl and Naphthalene 
A 100mg/L biphenyl and naphthalene stock solution was prepared by adding 
0.1000g of biphenyl and 0.1000g of naphthalene to a 1L volumetric flask topped to the 
volumetric line with LC/MS grade methanol. Biphenyl and naphthalene samples from 
10mg/L to 100mg/L in 10mg/L increments were prepared from the 100mg/L biphenyl 
and naphthalene stock solution using 100µL and 1000µL micropipettes to transfer to ten 
LC sample vials. 
 
2.15 Determination of the Limit of Linearity 
Ibuprofen 
A 100,000mg/L ibuprofen stock solution was prepared by adding 2.5000g of 
ibuprofen to a 25mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol, and all subsequent solutions prepared were topped to the volumetric line with 




10,000mg/L increments were prepared from the 100,000mg/L ibuprofen stock solution 
using volumetric pipettes to transfer to 5mL volumetric flasks after which were then 
transferred to ten LC sample vials. A 50,000mg/L ibuprofen stock solution was prepared 
by adding 0.5000g of ibuprofen to a 10mL volumetric flask. Ibuprofen samples from 
5,000mg/L to 30,000mg/L in 5,000mg/L increments were prepared from the 50,000mg/L 
ibuprofen stock solution using volumetric pipettes to transfer to 5mL volumetric flasks 
after which were then transferred to six LC sample vials. 
 
Benzoic Acid 
An 8,000mg/L benzoic acid stock solution was prepared by adding 0.2000g of 
benzoic acid to a 25mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol. Benzoic acid samples from 500mg/L to 5,000mg/L in 500mg/L increments 
were prepared from the 8,000mg/L benzoic acid stock solution using 100µL and 1000µL 
micropipettes to transfer to 5mL volumetric flasks topped to the volumetric line with 
LC/MS grade methanol after which were then transferred to ten LC sample vials. 
 
Biphenyl and Naphthalene 
A 1,200mg/L biphenyl and naphthalene stock solution was prepared by adding 
0.1200g of biphenyl and 0.1200g of naphthalene to a 100mL volumetric flask topped to 
the volumetric line with LC/MS grade methanol. Biphenyl and naphthalene samples from 
100mg/L to 1,200mg/L in 100mg/L increments were prepared from the 1,200mg/L 




transfer the stock solution to twelve LC sample vials after which the samples were diluted 
with LC/MS grade methanol. 
 
2.16 UHPLC Pump Conditioning Analysis 
 Samples for the UHPLC conditioning analysis were prepared by adding 0.1500g 
of ibuprofen and 0.1000g of benzoic acid to a 1L volumetric flask topped to the 
volumetric line with (40:60) 1% formic acid in water at pH 2.5 and acetonitrile mobile 
phase to produce a 150mg/L ibuprofen and 100mg/L benzoic acid stock solution using a 
3mL transfer pipette to transfer the stock solution to sixty LC sample vials. 
 
2.17 Calibration Methods 
External Calibration Method 
Ibuprofen 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with (40:60) 1% 
formic acid in water at pH 2.5 and acetonitrile mobile phase. A 300mg/L ibuprofen stock 
dilution was prepared by transferring 7.50mL of the 1,000mg/L ibuprofen stock solution 
using volumetric pipettes to a 25mL volumetric flask topped to the volumetric line with 
unmodified dissolution medium, and all subsequent dilutions were topped to the 
volumetric line with unmodified dissolution medium. A 222mg/L ibuprofen ‘unknown’ 
was prepared by transferring 5.55mL of the 1,000mg/L ibuprofen stock solution using 
volumetric pipettes to a 25mL volumetric flask after which 0.750mL was transferred 




to 300mg/L were prepared from the 300mg/L ibuprofen stock dilution using a 1000µL 
micropipette to transfer the stock dilution to five LC sample vials after which the samples 
were diluted. 
Biphenyl 
A 1,000mg/L biphenyl stock solution was prepared by adding 0.1000g of 
biphenyl to a 100mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol, and all subsequent dilutions were topped to the volumetric line with LC/MS 
grade methanol. A 100mg/L biphenyl ‘unknown’ was prepared by transferring 2.50mL of 
the 1,000mg/L biphenyl stock solution using volumetric pipettes to a 25mL volumetric 
flask. A 200mg/L biphenyl stock dilution was prepared by transferring 5.00mL of the 
1,000mg/L biphenyl stock solution using volumetric pipettes to a 25mL volumetric flask. 
Biphenyl standards from 20mg/L to 100mg/L were prepared from the 200mg/L biphenyl 
stock dilution using a 1000µL micropipette to transfer the stock dilution to five LC 
sample vials after which the samples were diluted. 
 
Standard Addition Method 
Ibuprofen 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with (40:60) 1% 
formic acid in water at pH 2.5 and acetonitrile mobile phase. A 500mg/L ibuprofen stock 
dilution was prepared by transferring 12.50mL of the 1,000mg/L ibuprofen stock solution 
using volumetric pipettes to a 25mL volumetric flask topped to the volumetric line with 
unmodified dissolution medium. A 222mg/L ibuprofen ‘unknown’ was prepared by 




to a 25mL volumetric flask after which 0.750mL was transferred using a 1000µL 
micropipette to one LC sample vial diluted with 0.750mL of unmodified dissolution 
medium. Ibuprofen standards from 50mg/L to 250mg/L were prepared from the 500mg/L 
ibuprofen stock dilution using a 1000µL micropipette to transfer the stock dilution to five 
LC sample vials after which 0.750mL of the 222mg/L ibuprofen ‘unknown’ was 
transferred using a 1000µL micropipette to the five LC sample vials containing the 
ibuprofen stock dilution. The five LC sample vials containing the 222mg/L ibuprofen 




A 1,000mg/L biphenyl stock solution was prepared by adding 0.1000g of 
biphenyl to a 100mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol. A 200mg/L biphenyl stock dilution was prepared by transferring 5.00mL of the 
1,000mg/L biphenyl stock solution using volumetric pipettes to a 25mL volumetric flask 
topped to the volumetric line with LC/MS grade methanol. A 100mg/L biphenyl 
‘unknown’ was prepared by transferring 2.50mL of the 1,000mg/L biphenyl stock 
solution using volumetric pipettes to a 25mL volumetric flask topped to the volumetric 
line with LC/MS grade methanol after which 0.750mL was transferred using a 1000µL 
micropipette to one LC sample vial diluted with 0.750mL of LC/MS grade methanol. 
Biphenyl standards from 20mg/L to 100mg/L were prepared from the 200mg/L biphenyl 
stock dilution using a 1000µL micropipette to transfer the stock dilution to five LC 




using a 1000µL micropipette to the five LC sample vials containing the biphenyl stock 
dilution. The five LC sample vials containing the 100mg/L biphenyl ‘unknown’, and the 
200mg/L biphenyl stock dilution were then diluted with LC/MS grade methanol. 
Internal Standard Method 
Ibuprofen and Benzoic Acid 
A 1,000mg/L ibuprofen stock solution was prepared by adding 0.1000g of 
ibuprofen to a 100mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol. A 1,000mg/L benzoic acid stock solution was prepared by adding 0.1000g of 
benzoic acid to a 100mL volumetric flask topped to the volumetric line with LC/MS 
grade methanol. A 222mg/L ibuprofen ‘unknown’ was prepared by transferring 5.55mL 
of the 1,000mg/L ibuprofen stock solution using volumetric pipettes to a 25mL 
volumetric flask topped to the line with unmodified dissolution medium. A 300mg/L 
ibuprofen stock dilution was prepared by transferring 7.50mL of the 1,000mg/L 
ibuprofen stock solution using volumetric pipettes to a 25mL volumetric flask topped to 
the volumetric line with unmodified dissolution medium. A 150mg/L benzoic acid 
internal standard dilution was prepared by transferring 3.75mL of the 1,000mg/L benzoic 
acid stock solution using volumetric pipettes to a 25mL volumetric flask topped to the 
volumetric line with unmodified dissolution medium. Ibuprofen standards from 50mg/L 
to 150mg/L were prepared from the 300mg/L ibuprofen stock dilution using a 1000µL 
micropipette to transfer the stock dilution to five LC sample vials after which 0.750mL of 
the 150mg/L benzoic acid internal standard dilution was transferred using a 1000µL 
micropipette to the five LC sample vials containing the 300mg/L ibuprofen stock dilution 




dilution was transferred to the LC sample vial containing only the 150mg/L benzoic acid 
internal standard. The five LC sample vials containing the 300mg/L ibuprofen stock 
dilution and 150mg/L benzoic acid internal standard were then diluted with unmodified 
dissolution medium. 
 
Biphenyl and Naphthalene 
A 1,000mg/L biphenyl stock solution was prepared by adding 0.1000g of 
biphenyl to a 100mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol. A 1,000mg/L naphthalene stock solution was prepared by adding 0.1000g of 
naphthalene to a 100mL volumetric flask topped to the volumetric line with LC/MS 
grade methanol. A 100mg/L biphenyl ‘unknown’ was prepared by transferring 2.50mL of 
the 1,000mg/L biphenyl stock solution using volumetric pipettes to a 25mL volumetric 
flask topped to the line with LC/MS grade methanol. A 200mg/L biphenyl stock dilution 
was prepared by transferring 5.00mL of the 1,000mg/L biphenyl stock solution using 
volumetric pipettes to a 25mL volumetric flask topped to the volumetric line with LC/MS 
grade methanol. A 100mg/L naphthalene internal standard dilution was prepared by 
transferring 2.50mL of the 1,000mg/L naphthalene stock solution using volumetric 
pipettes to a 25mL volumetric flask topped to the volumetric line with LC/MS grade 
methanol. Biphenyl standards from 20mg/L to 100mg/L were prepared from the 200mg/L 
biphenyl stock dilution using a 1000µL micropipette to transfer the stock dilution to five 
LC sample vials after which 0.750mL of the 100mg/L naphthalene internal standard 
dilution was transferred using a 1000µL micropipette to the five LC sample vials 




0.750mL of the 100mg/L biphenyl ‘unknown’ dilution was transferred to the LC sample 
vial containing only the 100mg/L naphthalene internal standard. The five LC sample 
vials containing the 200mg/L biphenyl stock dilution and 100mg/L naphthalene internal 
standard were then diluted with LC/MS grade methanol. 
 
Standard Dilution Analysis Method 
Ibuprofen and Benzoic Acid 
A 300mg/L ibuprofen standard, 100mg/L benzoic acid internal standard, and 
222mg/L ibuprofen ‘unknown’ stock solution mixture was prepared by adding 0.5220g of 
ibuprofen and 0.1000g of benzoic acid to a 1L volumetric flask topped to the volumetric 
line with unmodified dissolution medium, and all subsequent solutions were diluted to 
the volumetric line with unmodified dissolution medium. A 1,000mg/L ibuprofen 
‘unknown’ stock solution was prepared by adding 0.1000g of ibuprofen to a 100mL 
volumetric flask. A 222mg/L ibuprofen ‘unknown’ was prepared by transferring 2.22mL 
of the 1,000mg/L ibuprofen ‘unknown’ stock solution using volumetric pipettes to a 
10mL volumetric. The SDA samples were then prepared by transferring 0.750mL of the 
300mg/L ibuprofen standard, 100mg/L benzoic acid internal standard, and 222mg/L 
ibuprofen ‘unknown’ stock solution mixture using a 1000µL micropipette to transfer to 
five LC sample vials which were then diluted using the 222mg/L ibuprofen ‘unknown’. 
A 300mg/L ibuprofen standard, 75.0mg/L benzoic acid internal standard, and 
222mg/L ibuprofen ‘unknown’ stock solution mixture was prepared by adding 0.5220g of 
ibuprofen and 0.0750g of benzoic acid to a 1L volumetric flask topped to the volumetric 




the volumetric line with unmodified dissolution medium. A 1,000mg/L ibuprofen 
‘unknown’ stock solution was prepared by adding 0.1000g of ibuprofen to a 100mL 
volumetric flask. A 222mg/L ibuprofen ‘unknown’ was prepared by transferring 2.22mL 
of the 1,000mg/L ibuprofen ‘unknown’ stock solution using volumetric pipettes to a 
10mL volumetric. The SDA samples were then prepared by transferring 0.750mL of the 
300mg/L ibuprofen standard, 75.0mg/L benzoic acid internal standard, and 222mg/L 
ibuprofen ‘unknown’ stock solution mixture using a 1000µL micropipette to transfer to 
four LC sample vials which were then diluted using the 222mg/L ibuprofen ‘unknown’. 
A 300mg/L ibuprofen standard, 150mg/L benzoic acid internal standard, and 
266mg/L ibuprofen ‘unknown’ stock solution mixture was prepared by adding 0.5664g of 
ibuprofen and 0.1500g of benzoic acid to a 1L volumetric flask topped to the volumetric 
line with unmodified dissolution medium, and all subsequent solutions were diluted to 
the volumetric line with unmodified dissolution medium. A 1,000mg/L ibuprofen 
‘unknown’ stock solution was prepared by adding 0.1000g of ibuprofen to a 100mL 
volumetric flask. A 266mg/L ibuprofen ‘unknown’ was prepared by transferring 2.66mL 
of the 1,000mg/L ibuprofen ‘unknown’ stock solution using volumetric pipettes to a 
10mL volumetric. The SDA samples were then prepared by transferring 0.750mL of the 
300mg/L ibuprofen standard, 150mg/L benzoic acid internal standard, and 266mg/L 
ibuprofen ‘unknown’ stock solution mixture using a 1000µL micropipette to transfer to 
five LC sample vials which were then diluted using the 266mg/L ibuprofen ‘unknown’. 
A 300mg/L ibuprofen standard, 150mg/L benzoic acid internal standard, and 
178mg/L ibuprofen ‘unknown’ stock solution mixture was prepared by adding 0.4776g of 




line with unmodified dissolution medium, and all subsequent solutions were diluted to 
the volumetric line with unmodified dissolution medium. A 1,000mg/L ibuprofen 
‘unknown’ stock solution was prepared by adding 0.1000g of ibuprofen to a 100mL 
volumetric flask. A 178mg/L ibuprofen ‘unknown’ was prepared by transferring 1.78mL 
of the 1,000mg/L ibuprofen ‘unknown’ stock solution using volumetric pipettes to a 
10mL volumetric. The SDA samples were then prepared by transferring 0.750mL of the 
300mg/L ibuprofen standard, 150mg/L benzoic acid internal standard, and 178mg/L 
ibuprofen ‘unknown’ stock solution mixture using a 1000µL micropipette to transfer to 
five LC sample vials which were then diluted using the 178mg/L ibuprofen ‘unknown’. 
 
Biphenyl and Naphthalene 
A 1,250mg/L biphenyl standard, naphthalene internal standard, and biphenyl 
‘unknown’ stock solution was prepared by adding 0.2500g of biphenyl and 0.1250g of 
naphthalene to a 100mL volumetric flask topped to the volumetric line with LC/MS 
grade methanol, and all subsequent solutions were diluted to the volumetric line with 
LC/MS grade methanol. A 1,250mg/L biphenyl ‘unknown’ stock solution was prepared 
by adding 0.1250g of biphenyl to a 100mL volumetric flask. A 50.0mg/L biphenyl 
standard, naphthalene internal standard, and biphenyl ‘unknown’ stock dilution was 
prepared by transferring 1.0mL of the 1,250mg/L biphenyl standard, naphthalene internal 
standard, and biphenyl ‘unknown’ stock solution using a volumetric pipette to a 25mL 
volumetric. A 50.mg/L biphenyl ‘unknown’ stock dilution was prepared by transferring 
1.0mL of the 1,250mg/L biphenyl ‘unknown’ stock solution using a volumetric pipette to 




50.0mg/L biphenyl standard, naphthalene internal standard, and biphenyl ‘unknown’ 
stock dilution using a 1000µL micropipette to transfer to ten LC sample vials which were 
then diluted using the 50.0mg/L biphenyl ‘unknown’ stock dilution. 
A 1,250mg/L biphenyl standard, naphthalene internal standard, and biphenyl 
‘unknown’ stock solution was prepared by adding 0.2500g of biphenyl and 0.1250g of 
naphthalene to a 100mL volumetric flask topped to the volumetric line with LC/MS 
grade methanol, and all subsequent solutions were diluted to the volumetric line with 
LC/MS grade methanol. A 1,250mg/L biphenyl ‘unknown’ stock solution was prepared 
by adding 0.1250g of biphenyl to a 100mL volumetric flask. A 50.0mg/L biphenyl 
standard, naphthalene internal standard, and biphenyl ‘unknown’ stock dilution was 
prepared by transferring 1.0mL of the 1,250mg/L biphenyl standard, naphthalene internal 
standard, and biphenyl ‘unknown’ stock solution using a volumetric pipette to a 25mL 
volumetric. A 50.mg/L biphenyl ‘unknown’ stock dilution was prepared by transferring 
1.0mL of the 1,250mg/L biphenyl ‘unknown’ stock solution using a volumetric pipette to 
a 25mL volumetric. SDA samples were then prepared by transferring 0.500mL of the 
50.0mg/L biphenyl standard, naphthalene internal standard, and biphenyl ‘unknown’ 
stock dilution using a 1000µL micropipette to transfer to ten LC sample vials which were 
then diluted using the 50.0mg/L biphenyl ‘unknown’ stock dilution. 
A 1,250mg/L biphenyl standard and naphthalene internal standard, and 
1,500mg/L biphenyl ‘unknown’ stock solution was prepared by adding 0.2750g of 
biphenyl and 0.1250g of naphthalene to a 100mL volumetric flask topped to the 
volumetric line with LC/MS grade methanol, and all subsequent solutions were diluted to 




solution was prepared by adding 0.1500g of biphenyl to a 100mL volumetric flask. A 
50.0mg/L biphenyl standard and naphthalene internal standard, and 60.0mg/L biphenyl 
‘unknown’ stock dilution was prepared by transferring 1.0mL of the 1,250mg/L biphenyl 
standard and naphthalene internal standard, and 1,500mg/L biphenyl ‘unknown’ stock 
solution using a volumetric pipette to a 25mL volumetric. A 60.mg/L biphenyl 
‘unknown’ stock dilution was prepared by transferring 1.0mL of the 1,500mg/L biphenyl 
‘unknown’ stock solution using a volumetric pipette to a 25mL volumetric. SDA samples 
were then prepared by transferring 0.500mL of the 50.0mg/L biphenyl standard and 
naphthalene internal standard, and 60.0mg/L biphenyl ‘unknown’ stock dilution using a 
1000µL micropipette to transfer to ten LC sample vials which were then diluted using the 
60.0mg/L biphenyl ‘unknown’ stock dilution. 
A 1,250mg/L biphenyl standard and naphthalene internal standard, and 
1,000mg/L biphenyl ‘unknown’ stock solution was prepared by adding 0.2250g of 
biphenyl and 0.1250g of naphthalene to a 100mL volumetric flask topped to the 
volumetric line with LC/MS grade methanol, and all subsequent solutions were diluted to 
the volumetric line with LC/MS grade methanol. A 1,000mg/L biphenyl ‘unknown’ stock 
solution was prepared by adding 0.1000g of biphenyl to a 100mL volumetric flask. A 
50.0mg/L biphenyl standard and naphthalene internal standard, and 40.0mg/L biphenyl 
‘unknown’ stock dilution was prepared by transferring 1.0mL of the 1,250mg/L biphenyl 
standard and naphthalene internal standard, and 1,000mg/L biphenyl ‘unknown’ stock 
solution using a volumetric pipette to a 25mL volumetric. A 40.mg/L biphenyl 
‘unknown’ stock dilution was prepared by transferring 1.0mL of the 1,000mg/L biphenyl 




were then prepared by transferring 0.500mL of the 50.0mg/L biphenyl standard and 
naphthalene internal standard, and 40.0mg/L biphenyl ‘unknown’ stock dilution using a 
1000µL micropipette to transfer to ten LC sample vials which were then diluted using the 
40.0mg/L biphenyl ‘unknown’ stock dilution. 
 
2.18 Instrumentation 
Agilent Cary 50 UV-Vis 
Dissolution Testing Samples 
The instrument was configured for an acquisition time of 1.0000 second, a Y 
Mode of absorbance, and a Read Mode of 221nm for ibuprofen. A blank was prepared 
using the appropriate dissolution medium to zero the instrument after which the blank 
was analyzed five times. Each of the ten calibrators and samples were analyzed in 
triplicate after which the external calibration method was used to determine the 
concentration of the samples. 
 
Lambda Max 
The instrument was configured for an X Mode from 200nm to 300nm, a Y Mode 
of absorbance, a dual Beam Mode, and a Baseline correction. The Scan Controls were 
configured using an Average Time of 0.5000 seconds, a Data Interval of 0.50nm, and a 
Scan Rate of 60.00nm/minute. A blank was prepared using the appropriate matrix to 
measure a baseline correction after which each sample was analyzed to determine the 





Limit of Detection and Limit of Quantitation 
The instrument was configured for an acquisition time of 1.0000 second, a Y 
Mode of absorbance, and a Read Mode of 221nm for ibuprofen. A blank was prepared 
using the appropriate dissolution medium to zero the instrument after which the blank 
was analyzed seven times. Each of the ten calibrators were analyzed in triplicate and the 
lowest concentration calibration was analyzed seven times. 
 
Shimadzu Nexera X2 UHPLC/UV-Vis 
Ibuprofen and Benzoic Acid 
A C18 100mm L x 4.6mm i.d. with a 5µm particle size Hypersil Gold reverse 
phase column was employed in the separation of ibuprofen and benzoic acid with a 
2.0mL/min flow rate, 10µL injection volume, and an oven temperature of 30.0oC. The 
mobile phase was a (40:60) 1% formic acid (v/v) in water at pH 2.5 and acetonitrile. A 
baseline correction was performed prior to all analyses. Ibuprofen was monitored at 
237nm and benzoic acid was monitored at 241nm. 
 
Biphenyl and Naphthalene 
A C18 100mm L x 4.6mm i.d. with a 5µm particle size Hypersil Gold reverse 
phase column was employed in the separation of biphenyl and naphthalene with a 
2.0mL/min flow rate, 10µL injection volume, and an oven temperature of 40.0oC. The 
mobile phase was a (30:70) water and acetonitrile. A baseline correction was performed 





2.19 Figures of Merit 
Limit of Detection and Limit of Quantitation 
The limit of detection was determined by multiplying the standard deviation of 
the seven analyses of the lowest concentration calibration by three then dividing it by the 
slope of the calibration curve (Equation 30), and the limit of quantitation was determined 
by multiplying the standard deviation of the seven analyses of the lowest concentration 
calibration by ten then dividing it by the slope of the calibration curve (Equation 31). 
 
External Calibration Method 
The concentration of the unknown (CA) was determined by subtracting the 
intercept (b) of the calibration curve from the signal of the unknown (SA), dividing it by 
the slope (kA) of the calibration curve, and then multiplying by its dilution factor 
(Equation 9). 
 
Standard Addition Method 
The concentration of the unknown (CA) was determined by taking the absolute 
value of the negative intercept (-b) of the calibration curve divided by the slope (m) of the 
calibration curve, and then multiplying by its dilution factor (Equation 12). 
 
Internal Standard Method 
The concentration of the unknown (CA) was determined by dividing the signal of 




calibration curve was then subtracted, which was then divided by the slope (m) of the 
calibration curve, and then multiplying by its dilution factor (Equation 20). 
 
Standard Dilution Analysis 
The concentration of the unknown (𝐶𝐴
𝑆𝑎𝑚) was determined by dividing the slope 
(m) of the calibration curve by the intercept (b) of the calibration curve multiplied by the 
concentration of the standard (𝐶𝐴
𝑆𝑡𝑑) divided by the concentration of the internal standard 
(CI) (Equation 25). 
 
Percent Error 
The percent error was calculated by taking the absolute value of the experimental 
value subtracted from the theoretical value, divided by the theoretical value, and then 
multiplied by one hundred (Equation 28). 
 
Percent Relative Standard Deviation 
 The percent relative standard deviation was calculated by dividing the standard 
deviation (s) of the analysis by the mean (?̅?) of the analysis, and then multiplied by one 





CHAPTER 3 – RESULTS AND DISCUSSION 
3.10 Dissolution Testing of Ibuprofen Tablets 
The dissolution testing of the 200mg ibuprofen tablets was performed as per the 
USP35-NF30 monograph for ibuprofen tablets in which 900mL of unmodified 
dissolution medium at 37oC was placed in each vessel using apparatus 2, the paddles, as 
the agitating device. The six 200mg ibuprofen tablets were dropped into the vessels, the 
paddles were engaged at 50rpm, and the timer started. The test was performed for one 
hour and the samples were drawn from each vessel and secured every ten minutes. A UV-
Vis analysis was first performed on ibuprofen in unmodified dissolution medium to 
validate ibuprofens documented lambda max of 221nm, as seen below in Figure 3. 
 
 
Figure 3: Results for the Cary 50 Analysis of Ibuprofen in Unmodified 
Dissolution Medium 
 
 The external calibration method was then performed via UV-Vis analysis at 




from 2.0ppm to 12ppm to prepare a calibration curve, as seen below in Table 5 and 
Figure 4. 
 




Figure 4: Results for the Cary 50 Analysis Calibration Curve for Ibuprofen at 
221nm in Unmodified Dissolution Medium 
 
 The calibration curve equation was then used to quantify the percent of dissolved 
ibuprofen in each of the samples to produce a dissolution profile. It was observed that the 
required tolerance (Q) of not less than 80% dissolved in one hour had been met within 
Instrument Analytes Baseline Correction Analysis Wavelength (nm)
Cary 50 IBU / AA / CAF Dissolution Medium Dissolution Samples (ECM) 221
Cary 50 IBU / AA / Mixture Dissolution Medium Lambda Max (Scan) 200-300
Cary 50 IBU / CAF / Mixture Dissolution Medium Lambda Max (Scan) 200-300
Cary 50 IBU / BA / Mixture Mobile Phase A Lambda Max (Scan) 200-260
Cary 50 IBU / AA / CAF / BA Dissolution Medium LOD and LOQ 221
UHPLC IBU / BA Mobile Phase A LOL 237 (IBU) and 241 (BA)
UHPLC IBU Mobile Phase A ECM and SAM 237
UHPLC IBU / BA Mobile Phase A ISM 237 (IBU) and 241 (BA)




thirty minutes thus reducing all subsequent dissolution tests to thirty minutes, as seen 
below in Figure 5. 
 
 
Figure 5: Results for the CARY 50 Analysis of the Initial Dissolution Testing 
Profile for Ibuprofen Using 900mL Per Vessel of Unmodified 
Dissolution Medium at 37oC with an Apparatus Speed of 50rpm 
Performed in Triplicate Using Six 200mg Ibuprofen Tablets Per Test 
 
 Three separate dissolution tests of the 200mg ibuprofen tablets were then 
performed. The tests were performed for thirty minutes, and the samples drawn from the 
vessels and secured every ten minutes. The external calibration method was then 
performed via UV-Vis Analysis at 221nm on each of the fifty-four ibuprofen dissolution 
samples and the calibration curve equation used to quantify the percent of dissolved 
ibuprofen in each of the samples to produce three dissolution profiles superimposed onto 






Figure 6: Results for the CARY 50 Analysis of the Triplicate Dissolution 
Testing Profiles for Ibuprofen Using 900mL Per Vessel of Unmodified 
Dissolution Medium at 37oC with an Apparatus Speed of 50rpm 
Performed Each in Triplicate Using Six 200mg Ibuprofen Tablets Per 
Test 
 
 It was observed that the samples drawn at the ten-minute mark produced an error 
between 4% and 10% with a 7% average and an 8.8% relative standard deviation, as seen 
above in Figure 6 and below in Table 6. 
 
Table 6: Results for the CARY 50 Analysis of the Dissolution Testing Results of 
Ibuprofen in Unmodified Dissolution Medium 
 
 
Time (min) % Dissolved (1) % Dissolved (2) % Dissolved (3) % Dissolved (   ) %RSD
10 84 ±4 83 ±6 80 ±10 82 ±7 8.8
20 98 ±2 96 ±4 97 ±3 97 ±3 2.8





 The dissolution testing medium was then modified with ascorbic acid and three 
separate dissolution tests of the 200mg ibuprofen tablets were then performed in 
triplicate, seen below in Figure 7. 
 
Figure 7: Structure of Ascorbic Acid35 
 
The tests were performed for thirty minutes, and the samples drawn from the 
vessels and secured every ten minutes. The external calibration method using ibuprofen 
standards from 2.0ppm to 20ppm to prepare a calibration curve was then performed via 
UV-Vis analysis at 221nm on each of the fifty-four ascorbic acid modified ibuprofen 
dissolution samples, as seen below in Figure 8. 
 
 
Figure 8: Results for the Cary 50 Analysis Calibration Curve for Ibuprofen at 





 The calibration curve equation was then used to quantify the percent of dissolved 
ibuprofen in each of the ascorbic acid modified samples to produce three dissolution 
profiles superimposed onto one dissolution profile, as seen below in Figure 9. 
 
Figure 9: Results for the CARY 50 Analysis of the Triplicate Dissolution 
Testing Profile for Ibuprofen Using 900mL Per Vessel of Ascorbic 
Acid Modified Dissolution Medium at 37oC with an Apparatus Speed 
of 50rpm Performed Each in Triplicate Using Six 200mg Ibuprofen 
Tablets Per Test 
 
 It was observed that the samples drawn at the ten-minute mark produced the same 
error between 4% and 10% with the same 7% average but with a higher relative standard 
deviation of 9.3%, as seen above in Figure 9 and below in Table 7. 
 
Table 7: Results for the CARY 50 Analysis of the Dissolution Testing of Ibuprofen in 
Ascorbic Acid Modified Dissolution Medium 
 
Time (min) % Dissolved (1) % Dissolved (2) % Dissolved (3) % Dissolved (   ) %RSD
10 80 ±4 84 ±5 72 ±10 79 ±7 9.3
20 92 ±2 97 ±2 90 ±3 93 ±2 2.5





 The dissolution testing medium was then modified with caffeine and three 
separate dissolution tests of the 200mg ibuprofen tablets were then performed in 
triplicate, as seen below in Figure 10. 
 
 
Figure 10: Structure of Caffeine33 
 
The tests were performed for thirty minutes, and the samples drawn from the 
vessels and secured every ten minutes. The external calibration method using ibuprofen 
standards from 2.0ppm to 12ppm to prepare a calibration curve was then performed via 
UV-Vis analysis at 221nm on each of the fifty-four-caffeine modified ibuprofen 
dissolution samples, as seen below in Figure 11. 
 
 
Figure 11: Results for the Cary 50 Analysis Calibration Curve for Ibuprofen at 




 The calibration curve equation was then used to quantify the percent of dissolved 
ibuprofen in each of the caffeine modified samples to produce three dissolution profiles 
superimposed onto one dissolution profile, as seen below in Figure 12. 
 
 
Figure 12: Results for the CARY 50 Analysis of the Triplicate Dissolution 
Testing Profile for Ibuprofen Using 900mL Per Vessel of Caffeine 
Modified Dissolution Medium at 37oC with an Apparatus Speed of 
50rpm Performed Each in Triplicate Using Six 200mg Ibuprofen 
Tablets per Test 
 
 It was observed that the samples drawn at the ten-minute mark produced the 
lowest error between 5% and 8% with a lower average of 6% and a lower relative 





Table 8: Results for the CARY 50 Analysis of the Dissolution Testing of Ibuprofen in 
Caffeine Modified Dissolution Medium 
 
 
 The results of each of the three dissolution tests performed in triplicate were then 
averaged to produce an unmodified, ascorbic acid modified, and caffeine modified 
dissolution profile. It was observed that in the presence of ascorbic acid the dissolution 
rate of ibuprofen decreased between 3% to 4% with the same error of 7% at the ten-
minute mark, a lower error of 2% at the twenty minute mark, and a higher error of 3% at 
the thirty minute mark. In the presence of caffeine, the dissolution rate of ibuprofen 
increased 1% at the ten minute and thirty minute marks with a lower error of 6% at the 
ten minute mark, a lower error of 2% for the twenty minute mark, and the same error of 




Time (min) % Dissolved (1) % Dissolved (2) % Dissolved (3) % Dissolved (   ) %RSD
10 87 ±5 80 ±8 82 ±5 83 ±6 7.1
20 98 ±2 98 ±3 94 ±3 97 ±2 2.4






Figure 13: Results for the CARY 50 Analysis of the Triplicate Dissolution 
Testing Profile of the Averaged Results for Ibuprofen Using 900mL 
Per Vessel Per Test of Unmodified, Ascorbic Acid Modified, and 
Caffeine Modified Dissolution Medium at 37oC with an Apparatus 
Speed of 50rpm Performed Each in Triplicate Using Six 200mg 
Ibuprofen Tablets Per Test 
 
 The consistently high percent error and percent relative standard deviations for 
the ten-minute mark were attributed to the varying times necessary for the coating, 
consisting of pharmaceutical glaze, stearic acid, titanium dioxide, and sucrose, to open 
up.34,35 The increased dissolution rate of ibuprofen in the presence of caffeine was 
attributed to the ability of caffeine to increase the solubility of ibuprofen by ten-fold due 
to eutectic physical interactions thus increasing its hygroscopicity which in turn increases 
the dissolution rate and bioavailability of ibuprofen.36 The decreased dissolution rate of 
ibuprofen seen with ascorbic acid is consistent with previous research that evaluated the 
disintegration rates of immediate release pain medications in the presence of calcium 




significantly decreased. The disintegration tests evaluated the rate of the breakdown of 
the ibuprofen tablets into small fragments or granules directly affecting the dissolution 
rate, or the rate at which the tablet fully dissolves into solution.14, 37 
 
3.11 Determination of Lambda Max for Ibuprofen 
The determination of the lambda max for ibuprofen both alone and in a mixture 
with ascorbic acid was performed to verify that no summative effects occurred that would 
require the separation of the components prior to measurement of ibuprofens signal by 
the detector. It was observed that the phosphate buffer signal for ibuprofen and ascorbic 
acid alone and in a mixture was 207.02nm, 201.51nm, and 206.07nm which is 0.0224 
absorbance units lower in the mixture, respectively, and there was no summative effect 
on the absorbance that occurred at ibuprofens lambda max of 221.93nm, 0.0281 
absorbance units lower in the mixture, thus separation of the components was not 
required to quantify ibuprofen in ascorbic acid modified dissolution medium, as seen 







Figure 14: Results for the Cary 50 Analysis of Ibuprofen, Ascorbic Acid, and 
Mixture in Unmodified Dissolution Medium for Summative Effect 
Determination 
 
Table 9: Results for the Cary 50 Determination of Lambda Max for Ibuprofen, 
Ascorbic Acid, and Mixture in Unmodified Dissolution Medium for 
Summative Effect Determination 
 
 
 The determination of the lambda max for ibuprofen both alone and in a mixture 
with caffeine was performed to verify that no summative effect on the absorbance of 
wavelengths occurred that would require the separation of the components prior to 
measurement of ibuprofens signal by the detector. It was observed that the phosphate 
buffer signal for ibuprofen and caffeine alone and in a mixture was 203.97nm, 209.47nm, 
and 211.98nm, respectively, and a summative effect on the absorbance of the phosphate 














buffer peak for ibuprofen at 203.97nm and caffeine at 209.47nm occurred producing a 
new peak for the phosphate buffer in the mixture at 211.98nm. A second summative 
effect on the absorbance occurred at the first isosbestic point where ibuprofens lambda 
max of 222.97nm and the tailing edge of the phosphate buffer peak for caffeine occurred 
concealing ibuprofens lambda max thus separation of the components via UHPLC was 
required to quantify ibuprofen in caffeine modified dissolution medium, as seen above in 
Table 5, and below in Figure 15 and Table 10. 
 
 
Figure 15: Results for the Cary 50 Analysis of Ibuprofen, Caffeine, and Mixture 







Table 10: Results for the Cary 50 Determination of Lambda Max for Ibuprofen, 
Caffeine, and Mixture in Unmodified Dissolution Medium for 
Summative Effect Determination 
 
 
 The selection of an internal standard was now necessary. The USP monograph for 
ibuprofen tablets employs valerophenone as the internal standard, but in an attempt to 
conserve resources valerophenone (Figure 16) was not selected.14 
 
 
Figure 16: Structure of Valerophenone38 
 
Benzoic acid was selected as the internal standard for the UHPLC/UV-Vis 
analysis of ibuprofen since it was readily available, as seen below in Figure 17. 
 
 
Figure 17: Structure of Benzoic Acid39 


















 The determination of the lambda max for ibuprofen and benzoic acid was 
performed to determine the wavelengths that would be monitored during the analysis of 
ibuprofen. It was observed that the lambda max of ibuprofen and benzoic acid in mobile 
phase A was 237.53nm and 240.98nm, respectively, after which the wavelengths selected 
for analysis were 237nm and 241nm, respectively, as seen above in Table 5, and below in 
Figure 18 and Table 11. 
 
 
Figure 18: Results for the Cary 50 Analysis of Ibuprofen and Benzoic Acid in 
Mobile Phase A for the Determination of the Wavelengths to Monitor 
Using UHPLC Analysis 
 
Table 11: Results for the Cary 50 Analysis of Ibuprofen and Benzoic Acid in 
Mobile Phase A for the Determination of the Wavelengths to Monitor 
Using UHPLC Analysis 
 
  
Copmpound λ (nm) Signal (Abs) UHPLC (nm)
Ibuprofen 237.53 1.4507 237
Benzoic Acid 240.98 1.8782 241




3.12 Determination of the LOD and LOQ for Ibuprofen 
The Limit of Detection and Limit of Quantitation for ibuprofen in unmodified, 
ascorbic acid modified, and caffeine modified dissolution medium was performed to 
determine if the matrix components would shift the limit of detection and limit of 
quantitation for ibuprofen. It was observed that in the presence of ascorbic acid the limit 
of detection and limit of quantitation for ibuprofen decreased by 0.0340ppm and 
0.116ppm, respectively, and in the presence of caffeine the limit of detection and limit of 
quantitation for ibuprofen increased by 0.253ppm and 0.840ppm, respectively, which 
confirmed the necessity for the UHPLC separation of the benzoic acid and matrix 
components prior to quantification of ibuprofen, as seen above in Table 5, and below in 
Table 12. 
 
Table 12: Results for the CARY 50 Determination of the Limit of Detection and Limit of 
Quantitation for Ibuprofen 
 
 
3.13 Separation of Ibuprofen and Benzoic Acid 
The USP monograph for ibuprofen tablets contains the UHPLC parameters for the 
separation of ibuprofen and valerophenone, as seen below in Table 13.14 
 
  
Matrix Slope (m) Std. Dev. (SX) R
2 LOD (mg/L) LOQ (mg/L)
Unmodified 0.0438 0.00069 0.9999 0.047 0.16
Ascorbic Acid 0.0448 0.00020 0.9994 0.013 0.044




Table 13: USP Instrumental Parameters for the UHPLC Analysis of Ibuprofen Tablets 
 
 
 However, if deviations must be made to the UHPLC parameters on the 
monograph the USP provides a list of allowed deviations, as seen below in Table 14.14 
 
Table 14: USP Allowed Deviations for UHPLC Analysis 
 
 
 The USP allowed deviations were employed to reduce the column length to 
100mm, increase the injection volume to 10µL, and substitute the 1% chloroacetic acid 
with 1% formic acid, as seen below in Table 15. 
 
Table 15: Modified USP Parameters for the UHPLC Analysis of Ibuprofen 
 
 
 Once the deviations had been selected the UHPLC separation of benzoic acid and 
ibuprofen was performed using automatic integration which contained many negative 
peaks and ghost peaks, but once manual integration was employed the separation was 
successful with retention times of 0.759min and 1.617min, respectively, and a total 
runtime of 2.0min, as seen below in Figure 19. 
Length (mm) Diameter (mm) Particle (um) Packing Flow (mL/min) Inj. (µL) Temp (oC) A (pH) B pH Adj. A:B
250 4.6 5.0 C18 2.0 5.0 30.0 3.0 ACN NH4OH 40:60
Column Parameters Chromatography Parameters
A
H2O and 1% C2H3ClO2
Column (L) Column (I.D.) Particle (Ld) Flow (mL/min) Temp (
o
C) Injection (µL) pH λmax (nm) Salt Level
±70%







One ±30% or 
Abs. ±10%
Length (mm) Diameter (mm) Particle (um) Packing Flow (mL/min) Inj. (µL) Temp (oC) A (pH) B pH Adj. A:B
100 4.6 5.0 C18 2.0 10.0 30.0 3.0 ACN NH4OH 40:60
Column Parameters Chromatography Parameters
A





Figure 19: Results for the UHPLC Separation of Ibuprofen and Benzoic Acid Using 
Manual Integration 
 
 The separation of benzoic acid produced a low number of theoretical plates with a 
high theoretical plate height and a low tailing factor indicative of a high dispersion of the 
chromatographic band and column equilibrations with a slight tailing asymmetry 
allowing for an easily resolved and reproducible peak. The separation of ibuprofen 
produced a high number of theoretical plates with a low theoretical plate height, a low 
tailing factor, with high resolution, and a selectivity factor greater than one indicative of a 
low dispersion of the chromatographic band and column equilibrations with a slightly 
higher tailing asymmetry than benzoic acid, and with excellent separation allowing for an 
easily resolved and reproducible peak, as seen above in Figure 19 and below in Table 16. 
 




Compound Rtime k' N HETP Tailing Resolution α
Benzoic Acid 0.759 0.500 1421 70.363 1.099 0 0




3.14 Determination of the LOL for Ibuprofen and Benzoic Acid 
It was observed that ibuprofen became nonlinear at 40,000ppm and when a set of 
lower concentration calibrations were analyzed it was observed that ibuprofen became 
nonlinear at 15,000ppm, as seen above in Table 5, and below in Figure 20 and Figure 21. 
 
 
Figure 20: Results for the UHPLC Analysis Calibration Curve in Absorbance 
Units for the Determination of the Limit of Linearity of Ibuprofen at 
237nm in Mobile Phase A 
 
 
Figure 21: Results for the UHPLC Analysis Calibration Curve in Absorbance 
Units for the Determination of the Limit of Linearity of Ibuprofen at 




 It was observed that benzoic acid became nonlinear at 1,500ppm, which was more 
observable when the lower concentration standards were charted, as seen below in Figure 
22 and Figure 23. 
 
 
Figure 22: Results for the UHPLC Analysis Calibration Curve in Absorbance 
Units for the Determination of the Limit of Linearity of Benzoic Acid 
at 241nm in Mobile Phase A 
 
 
Figure 23: Results for the UHPLC Analysis Calibration Curve in Absorbance 
Units for the Determination of the Limit of Linearity of Benzoic Acid 





3.15 Determination of the LDR for Ibuprofen and Benzoic Acid 
It was determined that the LDR for ibuprofen and benzoic acid was 0.16ppm to 
15,000ppm and 0.098ppm to 1,500ppm, respectively, as seen below in Table 17. 
 
Table 17: Results for the UHPLC Determination of the Linear Dynamic Range for 
Ibuprofen at 237nm and Benzoic Acid at 241nm in Mobile Phase A 
 
 
3.16 Quantification of Ibuprofen via Current Calibration Methods 
A 200mg ibuprofen tablet fully dissolved in 900mL of dissolution medium had a 
concentration of 222ppm. The external calibration method, standard addition method, and 
internal standard method were performed to determine the concentrations of ibuprofen 
and benzoic acid that would be compared to the standard dilution analysis method results. 
The external calibration method employed a 222ppm ibuprofen ‘unknown’ that was 
approximately in the middle of the ibuprofen standard range of 150ppm to 300ppm that 
resulted in the lowest error of 0.18%, as seen above in Table 5 and below in Figure 24 
and Table 25. 
 
Compound LOD (mg/L) LOQ (mg/L) LOL (mg/L)
Ibuprofen 0.047 0.16 15,000





Figure 24: Results for the UHPLC External Calibration Method Analysis of 
Ibuprofen at 237nm in Mobile Phase A 
 




The standard addition method employed a 111ppm ibuprofen ‘unknown’ that was 
approximately in the middle of the ibuprofen standard range of 50.0ppm to 250ppm that 
resulted in the highest error of 1.3%, as seen above in Table 5 and Table 18, and below in 
Figure 25. 
 
Method IBU Std (mg/L) BA Int (mg/L) IBU Unk (mg/L) Rec (mg/L) Slope Intercept R
2 Error (%)
ECM 300 NA 222 222.4 878.63 0 1.000 0.18
SAM 250 NA 111 112.5 948.46 103,679 0.9998 1.3





Figure 25: Results for the UHPLC Standard Addition Method Analysis of 
Ibuprofen at 237nm in Mobile Phase A 
 
 The internal standard method employed a 111ppm ibuprofen ‘unknown’ that was 
approximately in the middle of the ibuprofen standard range of 50.0ppm to 150ppm with 
a benzoic acid internal standard concentration of 75.0ppm that resulted in the second 
lowest error of 0.38%, as seen above in Table 5 and Table 18 and below in Figure 26. 
 
 
Figure 26: Results for the UHPLC Internal Standard Method Analysis of 






3.17 Quantification of Ibuprofen via Standard Dilution Analysis 
The standard dilution analysis method was then performed and employed a 
222ppm ibuprofen ‘unknown’ that was approximately in the middle of the ibuprofen 
standard range of 150ppm to 300ppm, selected due to the external calibration method 
analysis producing the lowest error of 0.18%, with a benzoic acid internal standard 
concentration of 100ppm. The standard dilution analysis produced an error of 11%, as 
seen above in Table 5 and Table 18, and below in Figure 27 and Table 19. 
 
 
Figure 27: Results for the UHPLC Standard Dilution Analysis of Ibuprofen at 
237nm and Benzoic Acid at 241nm in Mobile Phase A 
 




IBU Std (mg/L) BA Int (mg/L) IBU Unk (mg/L) Rec (mg/L) Slope Intercept R
2 Error (%)
300 100 222 197.6 22.622 0.3432 0.9999 11
250 62.5 222 196.3 21.195 0.4319 0.9996 12
300 150 266 228.0 27.242 0.2389 0.9991 14




 The standard dilution analysis method was performed a second time to evaluate 
the concentrations employed in the first analysis. Only the diluted samples were 
employed as per the initial publication of the standard dilution analysis method.24 The 
ibuprofen ‘unknown’ was just above the middle of the ibuprofen standard concentration 
range of 150ppm to 250ppm with a benzoic acid internal standard concentration of 
62.5ppm producing an error of 12%. This confirmed that the undiluted samples can be 
employed in the standard dilution analysis method, as seen above in Table 19 and below 
in Figure 28. 
 
Figure 28: Results for the UHPLC Standard Dilution Analysis of Ibuprofen at 
237nm and Benzoic Acid at 241nm in Mobile Phase A 
 
 The sensitivity of the standard dilution analysis method was then evaluated by 
adjusting the ibuprofen ‘unknown’ by ±20%. The third standard dilution analysis 
employed a 266ppm ibuprofen ‘unknown’ that was at the high end of the ibuprofen 
standard range of 150ppm to 300ppm with a benzoic acid internal standard concentration 






Figure 29: Results for the UHPLC Standard Dilution Analysis of Ibuprofen at 
237nm and Benzoic Acid at 241nm in Mobile Phase A Increasing the 
Ibuprofen Unknown Concentration by 20% 
 
 The fourth standard dilution analysis employed a 178pm ibuprofen ‘unknown’ 
that was slightly below the middle of the ibuprofen standard range of 150ppm to 300ppm 
with a benzoic acid internal standard concentration of 150ppm producing an error of 







Figure 30: Results for the UHPLC Standard Dilution Analysis of Ibuprofen at 
237nm and Benzoic Acid at 241nm in Mobile Phase A Decreasing the 
Ibuprofen Unknown Concentration by 20% 
 
 The first and second standard dilution analyses were performed on the same day, 
and the third and fourth standard dilution analyses were performed on the day after 
producing good ruggedness with only a 1% difference between the percent error for both 
analyses performed on the same days, as seen above in Table 19. 
 A baseline correction estimates the peak area irrespective of the background. 
Translational and rotational effects can directly affect, or interfere, with the recovery of 
an analyte depending on which calibration method is employed. Translational effects, or 
baseline interference, are considered a constant bias and cannot be corrected using the 
standard addition method or internal standard method but can be corrected applying a 
baseline correction. Rotational effects, or matrix effect, are considered a proportional bias 
and cannot be corrected using baseline correction but can be corrected using the standard 
addition method or internal standard method. The standard dilution analysis is an 




translational and rotational effects should be corrected for and thus cannot be the cause of 
the high error produced form the standard dilution analysis of ibuprofen.40 
  
3.18 UHPLC Pump Conditioning Analysis 
Sources such as leaks, incorrect compressibility values, faulty check valves, 
impure solvents, air bubbles, and obstructed inline filters increase the inconsistency in 
peak integration. Compressibility values of a mixture must be determined experimentally 
beforehand as incorrect compressibility values greatly affect the accuracy and precision 
of the flow rate. The increasing variability of peak integration that occurs causes an 
inverse relationship between the relative standard deviation and the flow rate that 
negatively affects the precision of the peak area. A UHPLC pump conditioning analysis 
was performed using ibuprofen and benzoic acid to assess the effect pump pressure 
ripples and back pressure have on the sensitivity of the integration and quantification of 
the chromatographic peaks due to a fluctuating flow rate.41 
 Ibuprofen and benzoic acid were separated via UHPLC and the signal versus the 
analysis number for each compound was charted. It was observed that ibuprofen and 
benzoic acid did not produce a consistent signal around the mean signal value, much 
variability occurred over 7 hours of 2-minute chromatograms, as seen below in Figure 31, 






Figure 31: Results for the UHPLC Pump Conditioning Analysis of Ibuprofen at 
237nm in Mobile Phase A 
 
 
Figure 32: Results for the UHPLC Pump Conditioning Analysis of Benzoic Acid 
at 241nm in Mobile Phase A 
 




Compound Max Area Min Area Mean Area Max Ratio Min Ratio Mean Ratio Max Rolling Min Rolling Mean Rolling
Ibuprofen 166486 156652 162246
Benzoic Acid 814681 805729 810324




The ratio of the signals of ibuprofen and benzoic acid were charted. A rolling 




Figure 33: Results for the UHPLC Pump Conditioning Analysis for the Ratio of 
Ibuprofen at 237nm and Benzoic Acid at 241nm in Mobile Phase A 
 
 
Figure 34: Results for the UHPLC Pump Conditioning Analysis for the Rolling 







3.19 Determination of Lambda Max for Biphenyl 
In the development of an advanced instrumental undergraduate laboratory 
experiment the chromatographic and UV-Vis responses of biphenyl and naphthalene 
(Figure 35) were thoroughly investigated and documented. The lack of the standard 
dilution analysis of ibuprofen to achieve an error lower than 11% led the research to 
employ biphenyl and naphthalene in an attempt to produce a lower percent error. 
 
 
Figure 35: Structures of Biphenyl and Naphthalene42,43 
 
The determination of the lambda max for biphenyl and naphthalene was 
performed to verify the previous wavelengths employed that would be monitored during 
this analysis of biphenyl. It was observed that the lambda max of biphenyl and 
naphthalene in mobile phase B was 248.52nm and 276.04nm, respectively. It was 
observed that two summative effects on the absorbance occurred at isosbestic points with 
the first at approximately 228nm and the second at approximately 270nm. It was 
observed that naphthalene produced multiple peaks desirable for UHPLC analysis at 
approximately 258nm, 268nm, 276nm, and 287nm. Due to the isosbestic summative 
effect on the absorbance occurred at approximately 270nm the wavelengths selected for 
biphenyl and naphthalene analysis were 246nm and 268nm, respectively, as seen below 








Figure 36: Results for the Cary 50 Analysis of Biphenyl and Naphthalene in 
Mobile Phase B for the Determination of the Wavelengths to Monitor 
in UHPLC Analysis 
 
Table 22: Results for the Cary 50 Analysis of Biphenyl and Naphthalene in Mobile Phase 




Instrument Analytes Baseline Correction Analysis Wavelength (nm)
Cary 50 BPH / NAP / Mixture Mobile Phase B Lambda Max (Scan) 200-300
UHPLC BPH / NAP Mobile Phase B LOD and LOQ 246
UHPLC BPH / NAP Mobile Phase B LOL 246 (BPH) and 268 (NAP)
UHPLC BPH Mobile Phase B ECM and SAM 246
UHPLC BPH / NAP Mobile Phase B ISM 246 (BPH) and 268 (NAP)
UHPLC BPH / NAP Mobile Phase B SDA 246 (BPH) and 268 (NAP)















3.20 Separation of Biphenyl and Naphthalene 
The UHPLC parameters for naphthalene and biphenyl were selected from the 
previous UTNB experiment, as seen below in Table 23. 
 
Table 23: Instrumental Parameters for the UHPLC Analysis of Biphenyl 
 
 
 The separation of naphthalene and biphenyl was performed using automatic 
integration which contained two ghost peaks just above the baseline correction, but once 
manual integration was employed to reject the two ghost peaks the separation was 
successful with retention times of 1.182min and 1.379min, respectively, and a total 
runtime of 2.0min, as seen below in Figure 37. 
 
 
Figure 37: Results for the UHPLC Separation of Biphenyl and Naphthalene 
 
 The separation of naphthalene produced a low number of theoretical plates with a 
high theoretical plate height and a low tailing factor indicative of a high dispersion of the 
Length (mm) Diameter (mm) Particle (um) Packing Flow (mL/min) Inj. (µL) Temp (oC) A B A:B
100 4.6 5.0 C18 2.0 10.0 40.0 H2O ACN 30:70




chromatographic band and column equilibrations with a slight tailing asymmetry 
allowing for an easily resolved and reproducible peak. The separation of biphenyl 
produced a high number of theoretical plates with a low theoretical plate height, a low 
tailing factor, with high resolution, and a selectivity factor greater than one indicative of a 
low dispersion of the chromatographic band and column equilibrations with a slightly 
lower tailing asymmetry than naphthalene, and with good separation allowing for an 
easily resolved and reproducible peak, as seen below in Table 24. 
 
Table 24: Results for the UHPLC Separation of Biphenyl and Naphthalene 
 
 
3.21 Determination of the LOD and LOQ for Biphenyl and Naphthalene 
The Limit of Detection and Limit of Quantitation for biphenyl and naphthalene 
was performed to determine the lowest concentration of the linear dynamic range. It was 
observed that the limit of detection and limit of quantitation for biphenyl was 0.15ppm 
and 0.49ppm, respectfully, and naphthalene was 0.29ppm and 0.98ppm, respectfully, as 
seen above in Table 21 and below in Table 25. 
 
Table 25: Results for the UHPLC Determination of the Limit of Detection and Limit of 
Quantitation for Biphenyl and Naphthalene 
 
Compound Rtime k' N HETP Tailing Resolution α
Naphthalene 1.182 1.130 4295 23.281 1.234 0 0
Biphenyl 1.379 1.494 4985 20.456 1.211 2.615 1.313
Matrix Slope (m) Std. Dev. (SX) R
2 LOD (mg/L) LOQ (mg/L)
Biphenyl 33199 1600 0.9999 0.15 0.49




 It was observed that biphenyl became nonlinear at 400ppm, however, when only 
the lower concentration calibrations were charted, it was observed that biphenyl became 
nonlinear at 300ppm, as seen above in Table 21, and below in Figure 38 and Figure 39. 
 
 
Figure 38: Results for the UHPLC Analysis Calibration Curve for the 
Determination of the Limit of Linearity of Biphenyl at 246nm in 
Mobile Phase B 
 
 
Figure 39: Results for the UHPLC Analysis Calibration Curve for the 
Determination of the Limit of Linearity of Biphenyl at 246nm in 





3.22 Determination of the LOL for Biphenyl and Naphthalene 
It was observed that naphthalene became nonlinear at 400ppm, which was more 
observable when the lower concentration standards were charted, as seen below in Figure 
40 and Figure 41. 
 
Figure 40: Results for the UHPLC Analysis Calibration Curve for the 
Determination of the Limit of Linearity of Naphthalene at 268nm in 
Mobile Phase B 
 
 
Figure 41: Results for the UHPLC Analysis Calibration Curve for the 
Determination of the Limit of Linearity of Naphthalene at 268nm in 





3.23 Determination of the LDR for Biphenyl and Naphthalene 
It was determined that the LDR for biphenyl and naphthalene was 0.49ppm to 
300ppm and 0.98ppm to 400ppm, respectively, as seen below in Table 26. 
 
Table 26: Results for the UHPLC Determination of the Linear Dynamic Range for 
Biphenyl at 246nm and Naphthalene at 268nm in Mobile Phase B 
 
 
3.24 Quantification of Biphenyl via Current Calibration Methods 
The external calibration method, standard addition method, and internal standard 
method were performed to compare to the standard dilution analysis method results. The 
external calibration method employed a 50.0ppm biphenyl ‘unknown’ that resulted in the 




Figure 42: Results for the UHPLC External Calibration Method Analysis of 
Biphenyl at 246nm in Mobile Phase B 
Compound LOD (mg/L) LOQ (mg/L) LOL (mg/L)
Biphenyl 0.15 0.49 300








 The standard addition method employed a 50.0ppm biphenyl ‘unknown’ that 
resulted in the highest error of 14%, as seen above in Table 21 and Table 27, and below 
in Figure 43. 
 
 
Figure 43: Results for the UHPLC Standard Addition Method Analysis of 
Biphenyl at 246nm in Mobile Phase B 
 
 The internal standard method employed a 50.0ppm biphenyl ‘unknown’ and a 
naphthalene internal standard concentration of 50.0ppm that resulted in the lowest error 
of 3.4%, as seen above in Table 21 and Table 27, and below in Figure 44. 
Method BPH Std (mg/L) NAP Int (mg/L) BPH Unk (mg/L) Rec (mg/L) Slope Intercept R
2 Error (%)
ECM 100 NA 50.0 47.87 33,880 0 0.9999 4.3
SAM 100 NA 50.0 43.13 35,243 1,520,090 0.9994 14





Figure 44: Results for the UHPLC Internal Standard Method Analysis of 
Biphenyl at 246nm and Naphthalene at 268nm in Mobile Phase B 
 
3.25 Quantification of Biphenyl via Standard Dilution Analysis 
The standard dilution analysis method was then performed and employed a 
50.0ppm biphenyl “unknown” and a naphthalene internal standard concentration of 
50.0ppm that produced an error of 1.6%, as seen above in Table 21, and below in Figure 
45 and Table 28. 
 
 
Figure 45: Results for the UHPLC Standard Dilution Analysis of Biphenyl at 








 The standard dilution analysis method was performed a second time to evaluate 
the concentrations employed in the first analysis, however, only employing the diluted 
samples as per the initial publication of the method. The analysis employed a 50.0ppm 
biphenyl ‘unknown’ with a naphthalene internal standard concentration of 35.7ppm that 
produced the lowest error of 0.010% confirming for a second time that the undiluted 
samples can be employed in the standard dilution analysis method, as seen above in 
Table 20 and Table 28, and below in Figure 46.23 
  
BPH Std (mg/L) NAP Int (mg/L) BPH Unk (mg/L) Rec. (mg/L) Slope Intercept R
2 Error (%)
50.0 50.0 50.0 50.82 151.02 2.9716 0.9983 1.6
50.00 150.52 3.0106 0.9985 0.010
47.89 150.54 3.0599 0.9996 4.2
49.75 151.94 3.0540 0.9992 0.50
64.92 186.04 2.8655 0.9998 8.2
65.64 188.08 2.8653 0.9996 9.4
68.49 190.62 2.7831 0.9995 14
44.93 150.54 3.0599 0.9996 12
43.24 125.99 2.9138 0.9971 8.1









Figure 46: Results for the UHPLC Standard Dilution Analysis of Biphenyl at 
246nm and Naphthalene at 268nm in Mobile Phase B 
 
 The sensitivity of the standard dilution analysis method was then evaluated by 
adjusting the biphenyl ‘unknown’ by ±20%. The third standard dilution analysis 
employed a 60.0ppm biphenyl ‘unknown’ with a naphthalene internal standard 
concentration of 35.7ppm that produced an error of 8.2%, as seen above in Table 28 and 
below in Figure 47. 
 
 
Figure 47: Results for the UHPLC Standard Dilution Analysis of Biphenyl at 
246nm and Naphthalene at 268nm in Mobile Phase B Increasing the 




 The fourth standard dilution analysis employed a 40.0ppm biphenyl ‘unknown’ 
with a naphthalene internal standard concentration of 35.7ppm that produced an error of 
8.1%, as seen above in Table 28 and below in Figure 48. 
 
 
Figure 48: Results for the UHPLC Standard Dilution Analysis of Biphenyl at 
246nm and Naphthalene at 268nm in Mobile Phase B Decreasing the 
Biphenyl Unknown Concentration by 20% 
 
 The second, third, and fourth standard dilution analyses of biphenyl produced 
inconsistent percent errors of 0.10%, 4.2%, and 0.50% for the second analyses, 8.2%, 
9.4%, and 14% for the third analyses, and 12%, 8.1%, and 17% for the fourth analyses, as 
seen above in Table 28, Figure 46, Figure 47, and Figure 48. 
 The inconsistent percent errors for the standard dilution analysis of biphenyl and 
naphthalene were attributed to the pump pressure ripples and back pressure as with the 
standard dilution analysis of ibuprofen and benzoic acid, however, no pump conditioning 






 The empirical evidence gathered in the dissolution testing of ibuprofen tablets 
definitively established that ascorbic acid modified dissolution medium caused a decrease 
in the dissolution rate of ibuprofen, however, due to the percent errors produced in the 
dissolution testing of ibuprofen tablets in caffeine modified dissolution medium it cannot 
be definitively asserted that caffeine increased the dissolution rate of ibuprofen. 
 The complete figures of merit were achieved for the external calibration method, 
standard addition method, and internal standard method producing low percent errors for 
ibuprofen with higher percent errors produced for biphenyl. The figures of merit were not 
fully achieved in the standard dilution analysis of ibuprofen which produced high percent 
errors, however, low but inconsistent percent errors were achieved for biphenyl. 
 The high percent errors produced in the standard dilution analysis of ibuprofen led 
to the examination of the high pressure pumps employed in the UHPLC analyses to 
evaluate the effect of pump pressure ripples on the flow rate that resulted in the 
determination that there was disproportional variability in the response of ibuprofen and 
benzoic acid that may have also affected the response of biphenyl and naphthalene but was 
not confirmed through analysis. 
 In many high-risk high-reward research opportunities sometimes failures happen, 
however, in reflection solutions to problems that arose during the experimental phase are 
frequently illuminated providing the researcher with more appropriate directions to have 
taken such as: 1) The validation of the UHPLC modules and related functions such as the 
compressibility factor. 2) The validation of the internal standard valerophenone as per the 




dilution analysis experiment employing dyes. 4) Analyzing the dissolution samples 
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CHAPTER 5 – APPENDIX 
5.10 UHPLC Startup and Conditioning 
1. Make a logbook entry consisting of the date, time, your full name, what you will 
be using the UHPLC for, and your initials. Please remember to be precise in your 
entry. 
2. Remove, fold, and store the UHPLC cover in the second drawer beneath the 
administration computer. Be careful not to disturb the 900mL glass bottles when 
removing the cover. 
3. Remove the cardboard, plastic tub cover, and plastic tub from the first drawer 
beneath the administration computer as protection from solvents for the air vent 
grating on the UHPLC. 
4. Place the cardboard over the UHPLC air vent grating, cover the cardboard with 
the plastic tub cover, and then place the plastic tub upside down. Place the 900mL 
glass bottle on top of the upside-down plastic tub prior to refilling the solvents. 
5. Replace the solvents in each 900mL glass bottle with the solvents being used in 
the analysis. 
a. Line A is for aqueous/polar solvents, or solvents that produce vapors, and 
Line B is for organic/non-polar solvents. 
b. Using a funnel, fill each 900mL glass bottle with the solvent to be used in 
the analysis. 
c. Assure all diffusers are pushed to the bottom of each 900mL glass bottles 
then replace the bottle on the Velcro. This assures no movement of the 




6. Assure the desired column is installed correctly prior to powering up the UHPLC. 
a. If the installed column needs to be changed then contact Dr. Koether to 
assist you with changing the column. DO NOT attempt to change the 
column on your own. 
7. Turn on the administration system and then turn on the PowerVar to power up the 
UHPLC. 
a. Each of the UHPLC system module lights will turn green if operating 
correctly. 
8. Launch the LabSolutions software and then connect the administration system to 
the UHPLC. 
a. LabSolutions → Instrument → Shimadzu UHPLC. The Login is ‘Admin’ 
and there is no password. 
b. When the administration computer connects to the UHPLC controller you 
will hear two dissimilar beeps. This launches the ‘Realtime Analysis’ 
window. 
9. The ‘Shutdown Method File’ method file is loaded by default. This will be the 
method file you reload before shutting down the UHPLC. The ‘Shutdown Method 
File’ method file can be found in C:\LabSolutions\Data. 
10. Select the ‘Mobile Phase Settings’ button in the lower left frame of the ‘Realtime 
Analysis’ window. 
a. Enter the name of the solvent in the ‘Composition’ textbox of each pump 




b. Enter the volume of the solvent in the ‘Capacity’ textbox of each pump 
and rinse line. 
c. Do not modify the ‘Alarm Levels’ that are set at 20%. 
11. Prior to analysis both pumps and the autosampler must have the air purged from 
them. 
12. Open each right-side pump door by pressing inward until it clicks then let go to 
open, and then open the left pump door by pulling outward with very little force. 
a. Verify that the small bottles of 10% 2-propanol are filled to the red line. If 
not lightly unscrew the lid and fill to the red line. Close the lid, replace the 
bottle into the holding slot, and lightly close the left pump door. 
b. Turn the pump handles counterclockwise until the first horizontal position 
(9 O’clock). 
c. Press the ‘Purge’ button on both pumps while observing the plastic tubing 
for air bubbles and repeat the purge only if air bubbles remain. 
d. When purging is complete slowly and gently turn the pump valve handles 
clockwise until it is almost vertical and will not turn any further (11 
O’clock). 
e. Close the pump doors by pressing inward until it clicks then let go to 
remain closed. 
13. Purge the Autosampler by depressing the purge button on the front of the 
Autosampler. This will take 20 minutes. 
14. When the Autosampler has completed purging the UHPLC must be conditioned. 




15. Prior to conditioning the UHPLC a method file for your analysis must be created 
and configured. 
a. In the ‘Realtime Analysis’ window select File → New Method File after 
which the new method file configuration window will appear with 
multiple tabs. Only modify the tabs listed below. 
b. ‘Data Acquisition’ Tab 
i. ‘LC Program Time’ → ‘LC Stop Time’ 
1. Enter the analysis time for your sample. 
a. Select ‘Apply to All Acquisition Time’ 
c. ‘Pump’ Tab 
i. ‘Isocratic Flow’ 
1. Configured for the flow rate of each pump. 
2. Maximum pressure limit for each pump is 10,000 psi. 
ii. ‘Binary Gradient’ – Most commonly used. 
1. Configured for the flow rate of both pumps. 
2. Enter the percentage of Pump B being implemented. 
a. Do not edit ‘Pump B Curve’ unless you know what 
it does. 
3. Maximum pressure limit for both pumps is 10,000 psi. 
iii. ‘Compressibility Setting’ 
1. Select the check box to enter solvent settings. 
2. ‘Pump A’ 




3. ‘Pump B’ 
a. Organic/Non-polar solvent which produces low to 
no vapors. 
4. If the correct compressibility values are not entered 
quantification of the peaks will not be accurate nor precise. 
d. ‘MWD’ Tab 
i. Do not change the lamp from D2. 
ii. ‘Channel Setting’ 
1. Select ‘Chromatogram Type’ → ‘Parameters’ for each of 
the four channels, and do not edit other parameters. 
a. Absorbance – Most commonly used. 
i. Select desired wavelength and bandwidth. 
1. Averages from the ±nm selected. 
a. 254±4nm (Averages from 
250 to 258). 
b. Maxplot 
i. Select start and end wavelengths and 
bandwidth. 
1. Averages from the ±nm selected at 
the maximum absorbance found.  
c. Average 




1. Outputs chromatogram at the 
average wavelength between start 
and end wavelengths. 
e. ‘Column Oven’ Tab 
i. Set desired analysis temperature with the maximum temperature of 
90oC with ‘Ready Check’ turned on. 
16. After the parameters of your method file have been configured name your method 
file in the top right textbox containing the word ‘untitled’. Select ‘Download and 
Close’ at the bottom right to load your new method file. 
17. Once you select ‘Download and Close’ save the method file in a directory you 
create. 
a. File → Save Method File As → C:\LabSolutions\Data\Your Folder Name. 
18. On the bottom frame of the ‘Realtime Analysis’ window select ‘Oven On’ to turn 
on the oven and select ‘Pump On’ to turn the pumps on using your flow rate. 
Allow the UHPLC to condition for a minimum of two hours prior to starting your 
analysis. 
 
5.11 UHPLC Exporting Data for Excel 
1. Navigate to the working data directory where the UHPLC data file (.lcd) resides. 
2. Open the UHPLC data file (.lcd) in the ‘Postrun Analysis’ application by double 
clicking on it. 





4. The ‘Postrun Analysis’ application will open with the UHPLC data file selected. 
5. Verify it is the correct UHPLC data file before proceeding. 
6. Select the ‘File’ icon on the menu toolbar. 
7. Scroll down the ‘File’ menu to ‘Export Data’ and then select ‘Export Data as 
ASCII’ and the export window will appear. 
8. Select the radio button ‘Output File’ then select the desired parameters below for 
export in the ‘Output Items’ text box then select the location to be saved. 
a. Data File Properties – File and sample information. 
b. Peak Table – All peak information from the chromatogram. 
c. Identified Results – Quantitative information from the compound list. 
d. Grouping Results – Quantitative information from the group list. 
e. Status Trace – Status of pumps, degasser, sample cooler, oven temp, and 
room temp. 
f. Chromatogram – Retention time with absorbances for each wavelength 
channel. 
g. Slice Data – Multi-wavelength detector slice data for each wavelength 
channel. 
h. 3D Data – PDA data (if installed). 
i. Fraction Data – Fraction collection information. 
9. Select the folder icon for the ‘Output File’ and navigate to the working data 
directory to save the file. 
10. Name the file using the UHPLC data file (.lcd) name then click open. The 




11. Select the delimiter drop down and scroll to ‘Comma’ then click ‘Ok’ to close the 
window and save the file.  
12. Close the ‘Postrun Analysis’ application. 
13. Insert a USB thumb drive into the front panel of the computer system connected 
to the UHPLC instrument to copy the exported text file to the USB thumb drive. 
14. When importing ‘Headers’ and ‘Comma’ are selected for the imported data to be 
formatted correctly in excel. 
 
5.12 UHPLC PDF Report Creation 
1. Navigate to the working data directory where the UHPLC data file (.lcd) resides. 
2. Open the UHPLC data file (.lcd) in the ‘Postrun Analysis’ application by double 
clicking on it. 
3. Log into Lab Solutions to access the ‘Postrun Analysis’ application. 
4. The ‘Postrun Analysis’ application will open with the UHPLC data file selected. 
5. Verify it is the correct UHPLC data file before proceeding. 
6. Select the ‘File’ icon on the menu toolbar. 
7. Scroll down the ‘File’ menu to ‘Data Report’ and then select ‘PDF Output’. 
8. A window will open to save the ‘PDF Output’. 
9. Select the folder location for the ‘PDF Output’ and name the file before saving. 
10. Navigate to the saved file using windows explorer and verify its contents. 
11. Close the ‘Postrun Analysis’ application. 
12. Insert a USB thumb drive into the front panel of the computer system connected 





5.13 UHPLC Shutdown 
1. When your analysis is complete, navigate to the ‘Instrument’ menu item and 
select shutdown. 
 
a. The shutdown window will appear at which time you will select 
‘Shutdown Method File’, if not already checked, and you may have to 
navigate to C:\LabSolutions\Data to load the ‘Shutdown Method File.lcm’. 
 
b. Select ‘Degassing Unit (LC Pump, Subcontroller) Off after Cooldown’, if 
not already checked, and Select ‘Ok’. 
 
c. Wait for the UHPLC lights to turn amber, then close the ‘Realtime 





d. You will hear two dissimilar beeps when communication to the UHPLC is 
disconnected. 
e. Turn off the UHPLC using the PowerVar switch, shutdown the computer, 
and cover the UHPLC. 
i. If the Computer displays a ‘Shutdown Error’ select ‘Shut Down 
Anyway’. 
2. Enter ‘Shutdown and Covered’ into the logbook prior to leaving. 
 
5.14 UHPLC Waste Transfer 
1. Transfer the UHPLC connected waste to the stand-alone waste when changing the 
solvent system or when the level of solvent waste is four inches from the 
containers plumbing connector. 
 





3. Prior to moving the UHPLC connected waste out from the wall assure that you 
unclip the plastic clips connected to the structure below the UHPLC assuring that 
the inline plumbing connectors do not become disconnected. 
 
a. Assure that the pump plumbing connector does not become disconnected. 
 
4. Once the plumbing is free from the plastic clips move the UHPLC connected 
waste out from the wall, even with the front of the UHPLC structure, and then 
move the stand-alone waste next to the UHPLC connected waste. 
 
a. To prepare the UHPLC connected waste for transfer to the stand-alone 
waste the handle and lid of the UHPLC connected waste must be locked 




i. Move the handle towards the rear clamp. 
 
ii. Push on the front clamp to raise the teeth, move then handle 
forward until it is under the teeth, and then lower the teeth until 
they lock onto the handle. 
 
iii. Use your left hand to push on the rear clamp to raise the teeth, 
carefully move the handle towards the rear clamp until it is under 





iv. The lid is now locked open and the UHPLC connected waste 
container is prepared to be transferred to the stand-alone waste. 
 
v. Firmly grab the handle with your right hand while placing your left 
hand on the container behind the handle to assure a controlled 
transfer of the UHPLC connected waste to the stand-alone waste 
container using the large funnel. 
1. Only tip the UHPLC connected waste container until the 
black filter is parallel to the floor as to assure no waste 
flows into the filter. 
vi. Place the UHPLC connected waste container back into the 
overflow container and reverse the steps to lower the lid and 
unclamp the handle. 
vii. The funnel is then removed and the stand-alone waste container 
sealed with its lid, and then moved to the benchtop with the rear of 
it facing you. 






5. Correctly documenting the waste transfer. 
a. Wait until the solvent in the stand-alone waste container has settled from 
moving it. 
i. Take a sharpie and in the center of the rear of the waste container 
write your initials and the date, and then draw the solvent line to 
the left and right of your initials and date. 
 
ii. Place the stand-alone waste back into the overflow container, and 
then move it back to its original location. 
b. Log the transfer in the UHPLC logbook on the UHPLC administration 
computer, and the stand-alone waste clipboard log. 
c. Enter the solvent names and ratio along with the volume transferred in the 
UHPLC connected waste clipboard log. Return the clipboard logs to their 






5.15 UHPLC Sample Vial Reclamation 
1. Diluent is employed in reclaiming LC sample vials due to the analyte being 
miscible in it. 
a. If the diluent is not within access, too expensive, or pH adjusted water 
then determine another solvent the analyte is most miscible in to employ. 
2. Once UHPLC analysis is completed immediately empty the LC sample vials. If 
there are no saved caps then discard the punctured septa and retain the caps for 
future use. 
a. Rinse the LC sample vial caps with hot water, deionized water, and then 
dry them. 
i. If there are saved caps in a container then discard the caps and 
septa. 
3. Locate a beaker to hold all the LC sample vials in, but do not place them in the 
beaker. 
4. Fill the beaker with enough diluent to submerge half of the LC sample vials as the 
diluent level will increase with every LC sample vial added. 
5. Using a 3mL transfer pipette fill each LC sample vial with diluent from the 
beaker, submerge the LC sample vials in the beaker by dropping them, and then 
cover with parafilm. Assure no air bubbles are in the LC sample vials. 
a. Let the LC sample vials soak overnight. 
6. Decant the majority of diluent into a beaker and then transfer to a labelled plastic 
bottle, preferably nalgene, for future use. This avoids spillage of the diluent while 




7. Take the LC sample vials from the beaker, empty the diluent from them, rinse 
them with hot water, and then rinse them with deionized water. 
8. The LC sample vials are placed standing upright in small beakers then dried in an 
oven. 
9. After the LC sample vials have cooled inspect them for solute that dried to the 
vial walls. 
a. If there is no solute visible store them in a labeled plastic container. 
10. If solute has dried to the vial walls the process is repeated, however, a sonicator is 
employed. 
a. Place the LC sample vials into diluent as stated in step 5 but use an 
erlenmeyer flask that can be partially submerged in the sonicator using a 
ring stand and clamp. 
b. Assure the erlenmeyer flask is firmly secured to the ring stand using the 
clamp and submerge the erlenmeyer flask into the sonicator water just 
below the clamp. 
c. Sonicate for 30 minutes then repeat step 6 to step 9. 
 
5.16 UHPLC Flushing 
1. Prior to performing any analyses assure that the proper flushing solvent systems 
are prepared. 
a. Flushing the plumbing for salt buildup is performed if a buffer was 




i. The solvent system will be (90:10) LC grade water and methanol 
and must be filtered using no larger than a 0.45uM filter. 
1. The polar solvent reduces the lifetime of a high carbon load 
column (C18), so the column is removed and replaced with 
a coupling during this time. 
a. The coupling is stored with guard screws at the 
bottom of the column oven and the two wrenches 
are found in the bottom drawer under the UHPLC. 
ii. Runtime is 60 minutes of 2mL/min at 50% B with three 50uL 
injections and external rinsing. 
1. Each of the three 1L solvent bottles employed must have a 
minimum of 200mL to assure the diffusers remain 
submerged in solvent. 
a. If the diffusers are not submerged the pumps will 
draw air into the plumbing, which can cause 
damage to the pumps. 
2. The flush will consume 60mL of solvent each for Pump A 
and Pump B, 1.5mL for Rinse 0, and 1.5mL for the LC 
sample vial used for injections. 
3. A minimum of 723mL of solvent must be prepared, 
however, it is suggested to prepare 1L as the flush may 





a. The 1L Pump A and Pump B bottles will have a 
minimum of 260mL each, and the 1L Rinse 0 bottle 
will have a minimum of 203mL. 
iii. If the analysis was performed employing a buffer then proceed to 
outline number 2. 
b. Flushing the plumbing and column after any analysis is performed with no 
buffer employed OR after “Flushing the plumbing for salt buildup”  
i. The solvent system will be (75:15:10) LC grade water, methanol, 
and acetonitrile and must be filtered using no larger than a 0.45uM 
filter. 
1. The more nonpolar solvent will not reduce the lifetime of a 
high carbon load column (C18) and the column is not to be 
removed or must be reinstalled after the previous flushing 
with the coupling installed. 
ii. Runtime is 60 minutes at 50% B with three 50uL injections and 
external rinsing. 
1. If the column installed is ≥100mm L x 4.6mm I.D. x 5.0uM 
dp then 2mL/min. 
a. Each of the three 1L solvent bottles employed must 
have a minimum of 200mL to assure the diffusers 




i. If the diffusers are not submerged the pumps 
will draw air into the plumbing, which can 
cause damage to the pumps. 
b. The flush will consume 60mL of solvent each for 
Pump A and Pump B, 1.5mL for Rinse 0, and 
1.5mL for the LC sample vial used for injections. 
c. A minimum of 723mL of solvent must be prepared, 
however, it is suggested to prepare 1L as the flush 
may have to be extended due to heavy salt buildup 
in the column. 
i. The 1L Pump A and Pump B bottles will 
have a minimum of 260mL each, and the 1L 
Rinse 0 bottle will have a minimum of 
203mL. 
2. If the column installed is <100mm L x 4.6mm I.D. x 5.0uM 
dp then 1mL/min. 
a. Each of the three 1L solvent bottles employed must 
have a minimum of 200mL to assure the diffusers 
remain submerged in solvent. 
i. If the diffusers are not submerged the pumps 
will draw air into the plumbing, which can 




b. The flush will consume 30mL of solvent each for 
Pump A and Pump B, 1.5mL for Rinse 0, and 
1.5mL for the LC sample vial used for injections. 
c. A minimum of 663mL of solvent must be prepared, 
however, it is suggested to prepare 1L as the flush 
may have to be extended due to heavy salt buildup 
in the column. 
i. The 1L Pump A and Pump B bottles will 
have a minimum of 230mL each, and the 1L 
Rinse 0 bottle will have a minimum of 
203mL. 
c. If the analysis was performed without employing a buffer then proceed to 
outline number 3. 
2. Flushing the plumbing for salt buildup. 
a. Store the analysis solvent and load the flushing solvent. 
i. Label and prime three 1L nalgene bottles to store the solvent 
employed in analysis. 
ii. Configure the cardboard, tub lid, and tub as per the ‘Startup and 
Conditioning’ protocol. 
iii. When the analysis employing a buffer has been completed stop 
both pumps. 




1. Remove the lid and diffuser from the 1L Pump A UHPLC 
bottle and transfer the analysis solvent using a funnel to a 
labelled and primed 1L nalgene bottle. 
2. Label the 1L UHPLC bottle with the appropriate full names 
of the flushing solvents and do not use abbreviations or 
chemical formulas. 
3. Transfer the flushing solvent using a funnel to the 1L Pump 
A UHPLC bottle, insert the diffuser and secure the lid, 
replace it in the appropriate location on the solvent rack, 
and push the diffuser to the bottom of the bottle. 
a. Repeat for the Pump B and Rinse 0 1L UHPLC 
bottles. 
v. Store the tub, tub lid, and cardboard in the drawer it was found in. 
b. Removing the column and installing the coupling 
i. Assure that you have the authorization to remove the column. If 
you do not then contact Dr. Koether to assist you in this process as 
cross threading any screws will render the column useless, and the 
cost of a new column is from $800 to $2,000. 






iii. Remove the two wrenches used to uninstall and reinstall the 
column and coupling. 
 
iv. Match the correct side of each wrench to the input line nut and the 
column input line nut. 
 
v. While holding the wrench on the column input line nut turn the 
wrench on the input line nut clockwise to loosen the input line nut, 





vi. Loosen the output line screw by turning it counter-clockwise one 
turn. 
 
1. While holding the plastic output line screw remove the 
output line. 
 
a. Remove the output line screw completely and place 





vii. Remove the guard screws from the coupling and install them on 
the column, and then store the column at the bottom of the oven 
unit. 
 
viii. Prepare the coupling by installing the plastic output line screw with 
one turn clockwise. 
 
ix. Place the output line into the screw holding it with the index finger 
of the hand holding the coupling and then tighten the screw with 





x. Place the input line into the coupling and then tighten the screw by 
turning it counter-clockwise until it is snug, but do not overtighten. 
 
xi. Insert the coupling in the column mounting unit clamps. 
 
xii. Match the correct side of each wrench to the input line nut and 
coupling wrench location. 
1. While holding the wrench on the coupling wrench location 
turn the wrench on the input line nut counter-clockwise to 
tighten the input line nut, but do not overtighten. 
 
2. Close the oven doors and keep the toolkit wrenches 





c. Loading and Configuring the Flushing Method File 
i. Select the ‘_UHPLC Flush’ project folder by selecting ‘File-
>Select Project (Folder)’ and navigate to 
‘C:\LabSolutions\Data\_UHPLC Flush’ then click ‘OK’. 
ii. Select ‘File->Open Method File’ and then select the ‘UHPLC 
Flush.lcm’ method file. 
iii. Assure the method file ‘Pump’ tab is configured for a flow rate of 
2mL/min with 50% B, select ‘Download and Close’, and then 
select ‘File-> Save Method File’. 
iv. Fill a 1.5mL LC sample vial with the flushing solvent and then 
load the sample vial into Tray 1 in vial location ‘1’. 
d. Purging the Pumps and Autosampler. 
i. Once the sample vial has been loaded the air from both pumps 
must be purged. 
1. Open each right-side pump door by pressing inward until it 
clicks then let go to open, and then open the left pump door 
by pulling outward with very little force. 
a. Verify that the small bottles of 10% 2-propanol are 
filled to the red line. If not lightly unscrew the lid 
and fill to the red line. Close the lid, replace the 





b. Turn the pump handles counterclockwise until the 
first horizontal position (9 O’clock). 
c. Press the ‘Purge’ button on both pumps while 
observing the clear plastic tubing for air bubbles 
and repeat the purge only if air bubbles remain. 
d. When purging is complete slowly and gently turn 
the pump valve handles clockwise until it is almost 
vertical and will not turn any further (11 O’clock). 
2. Close the pump doors by pressing inward until it clicks 
then let go to remain closed then start the pumps and set 
your alarm for 1 hour. 
ii. Press the purge button on the front of the Autosampler which will 
take 20 minutes. 
e. Loading and running the flush batch file. 
i. Select ‘Main’ from the left pane and then select ‘Batch Editor. 
1. Select ‘File->Open->Batch File’, navigate to 
‘C:\LabSolutions\Data\_UHPLC Flush’, and then select 
‘UHPLC 3 Injection Flush.lcb’ batch file. 
ii. Select ‘Queue Batch Run’ from the left pane to start the batch file. 
1. This will inject 50uL of the flush solvent three times as to 
clean the inside of the autosampler needle where each 





f. Reinstalling the column. 
i. Once the Injections have been performed and one hour of flushing 
has surpassed the pumps are shut off and the column reinstalled. 
ii. Match the correct side of each wrench to the input line nut and 
coupling wrench location. 
 
iii. While holding the wrench on the coupling wrench location turn the 
wrench on the input line nut clockwise to loosen the input line nut 
then remove the input line by hand. 
 
iv. Remove the output line from the plastic screw in the coupling by 
turning the plastic screw one turn counter-clockwise and then 





v. Remove the output line screw by turning it counter-clockwise until 
it is out, remove the guard screws from the column and reinstall 
them in the coupling, and then store the coupling at the bottom of 
the oven unit. 
 
vi. Identify the column output by locating the flow direction arrow on 
the column label as the column output is in the direction of the 
flow arrow. 
 
vii. Reinstall the output line by inserting the output line screw into the 





viii. Place the output line into the screw holding it with the index finger 
of the hand holding the coupling and then tighten the screw with 
the other hand until it is snug, but do not overtighten. 
 
ix. Reinstall the input line by inserting the input line nut into the 
column input and tighten the input line nut by hand by turning the 
input line nut counter-clockwise until it is snug then replace the 
column back into the column mounting clamps. 
 
x. Match the correct side of each wrench to the input line nut and the 
column input line nut. 
1. While holding the wrench on the column input line nut turn 
the wrench on the input line nut counter-clockwise to 





2. If the input line nut is not tight enough small droplets of 
mobile phase will leak from the column input line when the 
pumps are turned on. 
a. If this occurs shut the pumps off, verify that the 
input line nut is not cross threaded, and then tighten 
the input line nut using a little more force than what 
was employed in the previous attempt. 
b. This can be repeated to assure that the input line nut 
is not overtightened. 
xi. Store the wrenches in the toolkit and store the toolkit in the drawer 
under the UHPLC. 
 
xii. Now perform the flushing the column in outline number 3. 
3. Flushing the plumbing and column after any analysis or after “Flushing the 
plumbing for salt buildup” 
a. When the analysis has been completed stop the flow by stopping the 
pumps. 
i. If the “Flushing the plumbing for salt buildup” was performed 
replace the coupling with the column employed in the analysis that 
employed a buffer. 




i. Label and prime three 1L nalgene bottles to store the solvent 
employed in analysis. 
ii. Configure the cardboard, tub lid, and tub as per the ‘Startup and 
Conditioning’ protocol. 
iii. When the analysis employing a buffer has been completed stop 
both pumps. 
iv. Exchange the analysis solvents quickly and safely. 
1. Remove the lid and diffuser from the 1L Pump A UHPLC 
bottle and transfer the analysis solvent using a funnel to a 
labelled and primed 1L nalgene bottle. 
2. Label the 1L UHPLC bottle with the appropriate full names 
of the flushing solvents and do not use abbreviations or 
chemical formulas. 
3. Transfer the flushing solvent using a funnel to the 1L Pump 
A UHPLC bottle, insert the diffuser and secure the lid, 
replace it in the appropriate location on the solvent rack, 
and push the diffuser to the bottom of the bottle. 
a. Repeat for the Pump B and Rinse 0 1L UHPLC 
bottles. 





c. Loading and Configuring the Flushing Method File 
i. Select the ‘_UHPLC Flush’ project folder by selecting ‘File-
>Select Project (Folder)’ and navigate to 
‘C:\LabSolutions\Data\_UHPLC Flush’ then click ‘OK’. 
ii. Select ‘File->Open Method File’ and then select the ‘UHPLC 
Flush.lcm’ method file. 
iii. Assure the method file ‘Pump’ tab is configured for a flow rate of 
2mL/min with 50% B, the ‘Oven’ tab is configured for 40oC, select 
‘Download and Close’, and then select ‘File-> Save Method File’. 
iv. Fill a 1.5mL LC sample vial with the flushing solvent and then 
load the sample vial into Tray 1 in vial location ‘1’. 
d. Purging the Pumps and Autosampler. 
i. Once the sample vial has been loaded the air from both pumps 
must be purged. 
1. Open each right-side pump door by pressing inward until it 
clicks then let go to open, and then open the left pump door 
by pulling outward with very little force. 
a. Verify that the small bottles of 10% 2-propanol are 
filled to the red line. If not lightly unscrew the lid 
and fill to the red line. Close the lid, replace the 





b. Turn the pump handles counterclockwise until the 
first horizontal position (9 O’clock). 
c. Press the ‘Purge’ button on both pumps while 
observing the clear plastic tubing for air bubbles 
and repeat the purge only if air bubbles remain. 
d. When purging is complete slowly and gently turn 
the pump valve handles clockwise until it is almost 
vertical and will not turn any further (11 O’clock). 
2. Close the pump doors by pressing inward until it clicks 
then let go to remain closed then start the pumps, turn the 
oven on, and set your alarm for 1 hour. 
ii. Press the purge button on the front of the Autosampler which will 
take 20 minutes. 
e. Loading and running the flush batch file. 
i. Select ‘Main’ from the left pane and then select ‘Batch Editor. 
1. Select ‘File->Open->Batch File’, navigate to 
‘C:\LabSolutions\Data\_UHPLC Flush’, and then select 
‘UHPLC 3 Injection Flush.lcb’ batch file. 
ii. Select ‘Queue Batch Run’ from the left pane to start the batch file. 
1. This will inject 50uL of the flush solvent three times as to 
clean the inside of the autosampler needle where each 





f. Store the flushing solvent and load the analysis solvent. 
i. Label and prime three 1L nalgene bottles to store the solvent 
employed in the flush. 
ii. Configure the cardboard, tub lid, and tub as per the ‘Startup and 
Conditioning’ protocol. 
iii. When the flushing has been completed stop both pumps. 
iv. Exchange the flushing solvents quickly and safely. 
1. Remove the lid and diffuser from the 1L Pump A UHPLC 
bottle and transfer the flushing solvent using a funnel to a 
labelled and primed 1L nalgene bottle. 
2. Label the 1L UHPLC bottle with the appropriate full names 
of the analysis solvents and do not use abbreviations or 
chemical formulas. 
3. Transfer the analysis solvent using a funnel to the 1L Pump 
A UHPLC bottle, insert the diffuser and secure the lid, 
replace it in the appropriate location on the solvent rack, 
and push the diffuser to the bottom of the bottle. 
a. Repeat for the Pump B (If Employed) and Rinse 0 
1L UHPLC bottles. 
i. If the one bottle method is employed in the 
analysis using only Pump A then do not 
remove the flushing solvent from the 1L 




v. Store the tub, tub lid, and cardboard in the drawer it was found in. 
g. Shutdown and Cover the UHPLC 
i. See the ‘Shutdown’ protocol. 
 
5.17 UHPLC Batch File Creation 
1. This protocol assumes that both standards and unknowns will be analyzed in the 
same batch file. 
2. Assure you have created and loaded the method file that will be employed in the 
batch analysis from the ‘Startup and Conditioning’ protocol prior to creating a 
batch file. 
a. The batch file uses the currently loaded method file parameters for the 
batch analysis. 
i. If a baseline check is to be employed the method file must be 
configured prior to the batch file creation. 
3. Select ‘Main->Batch Editor->Wizard’ from the left pane and the ‘Batch Table 
Wizard’ will appear. 
4. Batch Table Wizard. 
a. Assure the ‘Batch Table’ field appears as ‘New’ and the ‘Method File’ is 
the method file that is currently loaded. 
b. Select the desired injection volume and the number of ‘Sample Groups’ is 
set to 1. 
i. The UHPLC uses ‘Calibration Levels’ and not ‘Sample Groups’. 




i. All the parameters below can be modified when the wizard has 
been completed. 
5. Batch Table Wizard – Standard Sample. 
a. Enter the standard ‘Sample Name’ with a ‘001’ and then select ‘Auto-
Increment’ if you would like the Sample Names to be in order of analysis. 
b. Enter the ‘Sample ID’ with a ‘-0001’ and then select ‘Auto-Increment’ if 
you would like the Sample IDs to be in order of analysis. 
c. Enter the desired ‘Data File Name’ with a ‘001’ and then select ‘Auto-
Increment’ if you would like the ‘Data File Names’ to be in order of 
analysis. 
i. The ‘Create File Names’ automatically can be selected by 
checking the box above the ‘Data File Name’ field. 
d. Enter the ‘Number of Calibration Levels’, which can be up to ten. 
e. Enter the amount of ‘Standard Sample Vials Per Level’, or how many of 
identical concentrations of a specific standard is being employed. 
f. Enter the amount of ‘Repetitions per Run’, or the number of times to 
analyze each individual standard. 
g. Assure the correct ‘Tray’ is selected. 
i. The default tray is ‘Rack 1.5mL 105 Vials’. 
h. Select the starting vial number for your standards, which should be ‘Vial 
#1’. 
i. The UHPLC will insert the ending ‘Vial #’ according to the 




i. Select ‘Clear All Calibration Levels at the Beginning’ to initialize new set 
of calibrations, and then select ‘Next’. 
6. Batch Table Wizard – Unknown Sample. 
a. Enter the unknown ‘Sample Name’ with a ‘001’ and then select ‘Auto-
Increment’ if you would like the Sample Names to be in order of analysis. 
b. Enter the unknown ‘Sample ID’ with a ‘-0001’ and then select ‘Auto-
Increment’ if you would like the Sample IDs to be in order of analysis. 
c. Enter the desired unknown ‘Data File Name’ with a ‘001’ and then select 
‘Auto-Increment’ if you would like the ‘Data File Names’ to be in order of 
analysis. 
i. The ‘Create File Names’ automatically can be selected by 
checking the box above the ‘Data File Name’ field. 
d. Enter the amount of ‘Sample Vials in Each Group’, or the number of 
unknown samples loaded into the autosampler rack. 
e. Enter the amount of ‘Repetitions per Run’, or the number of times to 
analyze each individual unknown sample. 
f. The correct tray will be automatically selected from the configuration of 
the standards. 
g. The UHPLC will insert the beginning ‘Vial #’ according to the ‘Number 
of Calibration Levels’ that was entered. 
i. The UHPLC will insert the ending ‘Vial #’ according to the 
‘Number of Unknown Samples in Each Group’ that was entered. 




7. Batch Table Wizard – Other Settings 
a. If the method file was previously configured with a ‘Baseline Check’ then 
select ‘Baseline Check’, but f it was not then just select next. 
8. Batch Table Wizard – Save Batch File. 
a. Navigate to the project folder using the blue folder icon at the top right of 
the window, name the batch file, select open, and then select finish. 
9. The initial batch file will be displayed. 
a. Verify the ‘Vial #, Tray Name’ Sample Name’ Sample ID, Sample Type, 
Method File Name, and Data File Name’. 
b. If any field is incorrect then place the cursor in the column and row to be 
edited and enter the new information. 
10. Select ‘Queue Batch Run’ from the left pane to initiate the batch file analysis. 
 
5.18 UHPLC Manual Integration 
A basic understanding of the regulatory requirements is necessary prior to employing 
manual integration. 
1. An ‘Audit Trail’ must be established. 
a. A backup of ALL original data files and manually integrated data files 
must be retained for review. 
i. A second person is required to review ALL original data files and 





ii. If a run is to be discarded from quantitation the original data file 
must be retained. 
b. Regulatory documentation includes: 
i. Initial, repeated, and reported results. 
ii. Method employed (Standard Operating Procedures). 
iii. Assay run identification. 
iv. Analyst that is requesting and reasoning for the manual integration. 
v. Manager who authorized the manual integration. 
2. A justification and thorough explanation of the reasoning for the manual 
integration is required. 
a. Acceptable examples for inhibiting automatic integration functions. 
i. Baseline perturbations caused by sample injection. 
ii. USP impurity determinations. 
1. The API peak is automatically integrated, but the impurity 
peaks are manually integrated due to very low 
concentrations. 
iii. Analysis of metabolites or degradants that have very low 
concentrations near the LOQ. 
iv. Large amounts of noise and/or drift in the baseline. 
1. This may be caused by a need for system maintenance, a 





2. A common issue with manual integration is the 
repositioning of the baseline correction so that it produces 
inaccurate peak areas. 
b. Multiple re-integrations that are not justified are called “Integrating into 
Compliance”. 
3. Standard operating procedures must be developed, validated, and adhered to. 
a. Frequently developed for each compound or formulation that includes: 
i. Guidelines on when and how to employ manual integration. 
ii. Handling of extra peaks produced by excipients and impurities. 
iii. Tolerances for analyst adjustments in the manual integration 
parameters. 
b. Once validated the manual integration parameters developed for the 
standards MUST be employed with the unknown samples. 
c. Developing standard operating procedures with a scientific rationale. 
i. Perform an initial analysis on known standards and a prepared 
sample using automatic integration to calculate the recovery. 
ii. Evaluate each integration parameter by using the same known 
standards and prepared sample by modifying each parameter below 
to calculate the recovery. 
1. Slope sensitivity. 
2. Peak width. 
3. Bunching factor. 




5. Noise threshold. 
6. Area threshold. 
iii. Compare the recoveries to optimize the method of manual 
integration. 
4. Acceptable alternatives to consider before employing manual integration. 
a. Adjusting automatic integration or ‘Manual Intervention’. 
b. Optimization of the chromatographic method by modifying: 
i. The solvent system and/or solvent system ratio. 
ii. The flow rate and/or injection volume. 
iii. The column type, length, inner diameter, and/or particle size. 
iv. The column temperature. 
5. The baseline correction and peak identification process. 
a. The integration software initially establishes the baseline using the first 
data point after which it redefines the baseline by averaging the input 
signal. 
i. If the integration software fails to establish a redefined baseline the 
first data point is used for the initial baseline. 
b. The integration software continues to monitor the input signal determining 
a threshold for the baseline containing parameters for the noise threshold. 
i. It is periodically reset to compensate for drift until the up-slope of 






6. Examples of manual integration techniques, as seen below in Figure 1. 
a. Acceptable. 
i. (1) Manual integration of the peak applying a justifiable baseline. 
b. Unacceptable. 
i. (2) Manual integration that shaves the peak producing less area. 
ii. (3) Manual integration that enhances the peak producing more 
area. 
 
Figure 1: Data Integrity – Shaving and Enhancing Peaks2 
7. Manual integration must be employed prior to performing regression analysis. 
a. Performing regression analysis first will introduce bias when selecting to 





The following protocol on manual integration utilizes the LabSolutions software 
packaged with the Shimadzu Nexera X2 and will only employ the ‘Time Program Table’ 
displayed when the ‘Program’ command button is selected from the ‘Integration’ tab 
found in the ‘Method View’ of the ‘Calibration Curve’ window located in the left pane of 
the ‘Postrun Analysis’ or ‘Realtime Analysis’ windows after an analysis has been 
performed. This protocol will employ the ‘Postrun Analysis’ feature of the LabSolutions 
software and only manually integrate one peak of interest employing the integration 
window used by the automatic integration algorithm. The instructions in this protocol 
may be used to manually integrate more than one peak of interest if desired. A full list of 
commands with definitions, setting ranges, and default settings can be found in the 
‘Integration Time Program’ help file located in the ‘LabSolutions’ software. 
 
1. Perform an analysis to generate the data files to be used in the manual integration. 
a. Employ the standards and samples but do not perform regression analysis 
and retain the original copies in a separate folder. 
2. Determine the integration parameters to be employed. 
a. Open the ‘LabSolutions’ software found on the windows desktop, navigate 





b. The ‘Postrun Analysis’ window will appear after which the ‘Main’ tab at 
the top of the left windowpane is selected. 
 
c. The ‘Calibration Curve’ icon in the left windowpane is then selected. 
 





e. The project folder containing the method file employed in the analysis is 
then selected. 
 
i. A navigation window will appear to select the folder containing the 
method file employed in the analysis after which click ‘OK’. 
f. Once the project folder is selected open the method file used in the 
analysis. 
 
g. An empty calibration curve for the analysis associated with the method 
file will appear in the upper left windowpane with the data files in the 
upper right windowpane where each data file is displayed in the 





h. The retention time of the peak of interest must be determined by 
highlighting the data file in the ‘Data File’ windowpane and placing the 
mouse cursor at the apex of the peak of interest in the ‘Chromatogram 
View’. 
 
i. There will be slightly varying retention times depending on the 





1. The void volume peaks will not be retained in this protocol, 
however, for the ‘LabSolutions’ software to automatically 
perform the chromatographic calculations the void volume 
times will have to be manually integrated. 
i. Enter the median retention time in the ‘Compound Table’ by selecting 
‘Edit’ from the ‘Method View’ windowpane. 
 
i. Select ‘View’ to apply the changes and the ‘Calibration Curve’ 
windowpane will populate with the calibration curve for the 
standards. 
 
j. The negative peak from the analysis produced unacceptable integration 





i. All the chromatograms from this analysis will also have additional 
area so manual integration of the peak of interest is required. 
k. To determine the integration window to be employed the highest 
concentration standard data file is opened in read-only mode by double-
clicking the data file after which the chromatogram window for the data 
file will appear. 
i. The automatic integration points are denoted by an upward red 
arrow to a downward red arrow. By left clicking on the channel 
desired the channel peak will be highlighted as to differentiate 
which set of arrows to observe the time window. 
 
ii. Document the automatic integration time window for the peak of 




l. Enter ‘Edit’ mode, select the ‘Integration’ tab, and then select the 
‘Program’ icon. 
 
m. The ‘Integration Time Program’ window will then appear displaying the 
highlighted data file from the ‘Data File’ windowpane. 
 





a. On row 1 assure the time is ‘0.000’ in the ‘Time (min)’ column then select 
the open area of the ‘Command’ column and a dropdown list will appear 
to select “Integration Off’. 
b. On row 2 enter the starting time from the automatic integration in the 
‘Time (min)’ column and then select the open area of the ‘Command’ 
column and a dropdown list will appear to select ‘Integration On’. 
c. On row 3 enter the ending time from the automatic integration in the 
‘Time (min)’ column and then select the open area of the ‘Command’ 
column and a dropdown list will appear to select ‘Integration Off’, select 
‘Simulate’ to verify the integration, and then click ‘OK’. 
 
d. Select ‘Copy to All Channels’ on the ‘Integration’ tab of the ‘Method 
View’, select ‘Yes’ to copy to all channels, and then select ‘View’ to 





i. Applying the same time the automatic integration employed 
maintains the baseline integration determined by the algorithm 
without retaining the unwanted peaks. 
e. Save the method file and close the ‘Calibration Curve’ window. 
4. Applying the integration parameters to the samples. 
a. Open the sample data file in the ‘Postrun Analysis’ window by double-





b. Following steps 2l then 3a to 3d enter the identical integration time 
window that was employed with the standards for each sample data file, 
save the data files, and then close the window. 
 
c. Follow the ‘Exporting Data for Excel’ protocol to export the manually 
integrated data in .csv format to import into excel for the statistical 
treatment. 
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